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ABSTRACT 
Influenza A is one of the most prevalent and significant viral infections worldwide, 
resulting in annual epidemics and occasional pandemics. Upon infection, antiviral 
drugs targeting the neuraminidase protein and M2 protein are the only treatment 
options available. However, the emergence of antiviral drug resistance is concerning, 
therefore the aim of this work was to identify inhibitor molecules that may bind to 
highly conserved regions of selected internal influenza A proteins. Sequences of the 
non-structural protein 1 (NS1), nuclear export protein (NEP) and polymerase basic 
protein 2 (PB2) from all hosts and subtypes were aligned and the degree of amino 
acid conservation was calculated based on Valdar’s scoring method. Missing parts of 
the experimental structures were predicted using the I-TASSER server and ligand 
binding hot spots were identified with computational solvent mapping. Selected 
binding sites in conserved regions were subjected to virtual screening against two 
compound libraries using AutoDock Vina and AutoDock 4. Two out of twelve top hit 
compounds predicted to target the NS1 protein showed capability of reducing 
influenza A H1N1 replication in plaque reduction assays at concentrations below 100 
µM, although the target protein and mechanism of action could not be confirmed. For 
the NEP, conservation analysis was based on 3000 sequences and binding hot 
spots were located in common areas amongst three structures. Docking results 
revealed predicted binding affinities of up to -8.95 kcal/mol, and conserved amino 
acid residues interacting with top compounds include Arg42, Asp43, Lys39, Ile80, 
Gln101, Leu105, and Val109. For the PB2 protein, conservation analysis was based 
on ~12,000 sequences and fifteen potential binding hot spots were identified. 
Docking results revealed predicted binding affinities of up to -10.3 kcal/mol, with top 
molecules interacting with the highly conserved residues Gln138, Gly222, Ile539, 
Asn540, Gly541, Tyr531 and Thr530. The findings from this research could provide 
starting points for in vitro experiments, as well as the development of antiviral drugs 
that function to inhibit influenza A replication without leading to resistance.  
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1  INTRODUCTION 
1.1 The influenza A virus 
There are three main types of influenza (flu) virus: A, B and C, which cause a 
contagious respiratory illness in humans characterised by fever, cough, sore throat, 
headache and muscle pain. Infection with type A and B virus strains cause seasonal 
flu, which peaks during the winter months and ranges in severity depending on the 
immunocompetence level of the host. Infection with influenza C is much less 
common and is associated with mild illness only (Taubenberger & Morens, 2008).  
Besides human to human transmission via close contact or inhalation of virus 
droplets, influenza A displays zoonosis with wild aquatic birds being the natural 
reservoir (CDC, 2014). Therefore, the virus has the potential to be transmitted 
between various hosts such as birds, pigs, horses and whales amongst many other 
animals. Such cross-species transmission has lead to the formation of novel re-
assortant influenza A subtypes through mixing of viral genome segments (antigenic 
shift), conferring a dangerous increase in pathogenicity to the human population 
(Taubenberger & Kash, 2010). In addition to annual epidemics which may result in 
significant death rates, serious outbreaks have been reported in previous years due 
to reassortment events. This includes the 1918 Spanish flu pandemic killing over 40 
million people, the 1957 Asian flu pandemic, the 1968 Hong Kong flu pandemic and 
more recently, the 2009 Swine flu pandemic which resulted in approximately 284,000 
deaths worldwide within the first year of virus circulation (Dawood et al., 2012; 
Taubenberger & Kash, 2010). Influenza types B and C have a limited host range and 
do not cause pandemics; hence this work focuses on the discovery of antivirals 
targeting influenza A. 
Influenza A viruses are subtyped numerically according to antigenic properties of the 
hemagglutinin (HA) and neuraminidase (NA) surface proteins as HxNy, and to date, 
there are 18 different HA subtypes and 11 different NA subtypes identified (CDC, 
2014). The standard influenza A nomenclature consists of the antigenic type (e.g., A, 
B, C), host of origin, (for human-origin viruses, no host is given), geographical origin, 
strain number, year of isolation, and the HA and NA antigen description in 
parentheses, e.g. A/duck/Alberta/35/76 (H1N1). All subtypes are able to infect birds, 
14 
 
 
with the exception of H17N10 and H18N11, which have only been discovered in bats 
(Wu et al., 2014). The species affected by different HA and NA subtypes are shown 
in table 1. As certain subtypes are associated with poor clinical outcome in humans, 
influenza A infection is considered a major medical concern to public health.  
Table 1. Species affected by the different HA and NA influenza A subtypes, with wild aquatic 
birds being the main reservoir (table adapted from CDC, 2014). Both HA and NA proteins of 
the subtype must match to a host as they recognise the same cell surface receptor in order 
to establish infection (Mitnaul et al., 2000). 
HA 
SubType 
Humans Poultry Swine Bats/ 
Other 
NA 
SubType 
Humans Poultry Swine Bats/ 
Other 
H1     N1     
H2     N2     
H3    other 
animals 
N3     
H4    other 
animals 
N4     
H5     N5     
H6     N6     
H7    other 
animals 
N7    other 
animals 
H8     N8    other 
animals 
H9     N9     
H10     N10    Bats 
H11     N11    Bats 
H12          
H13          
H14          
H15          
H16          
H17    Bats      
H18    Bats      
 
Currently in the United Kingdom, a trivalent flu vaccine (usually composed of two 
type A strains and one type B) is formulated annually to protect against the expected 
circulating strains during the upcoming flu season. The vaccine composition varies 
due to strain variation, therefore circulation of the same subtype may require a 
different vaccine (Carrat & Flahault, 2007). Vaccination is highly recommended and 
considered to be the best means of preventing infection. For this reason, the vaccine 
is offered free of charge by the National Health Service to those considered to be at 
high risk, such as people aged over 65, young children, pregnant women, those with 
underlying health conditions and health care workers. However, the vaccine fails to 
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provide long term immunity due to antigenic drifts (gradual accumulation of changes 
in the HA and NA genes) which permit the virus to re-infect a host. In February 2015, 
the high rate of evolution of the virus was exemplified by a mutation in the circulating 
H3N2 vaccine strain. This severely impacted the effectiveness of the vaccine, which 
was estimated to be only 19% effective during the 2014/2015 season (CDC, 2017; 
Chambers, Parkhouse, Ross, Alby, & Hensley, 2015). Furthermore, in certain 
individuals response to vaccination is poor, and can lead to serious complications of 
flu, highlighting the need for effective, novel antivirals which are unlikely to be 
affected by resistance mutations to limit virus transmission. 
This chapter presents a review of influenza A virus biology, current antivirals and 
emerging inhibitors, and the rationale behind targeting evolutionary conserved 
binding sites of viral proteins. The work presented in subsequent chapters will focus 
on selected internal influenza proteins as antiviral targets, leading to the discovery of 
molecules that may serve as potential replication inhibitors.  
 
1.2 Structure and infectious cycle of the influenza A virus 
 
Influenza A belongs to the Orthomyxoviridae family of viruses which are 
characterised by a lipid bilayer envelope and a segmented, negative-sense single 
stranded RNA genome (figure 1a) (Cheung & Poon, 2007).  This genome is ~13,600 
base pairs in length and comprises eight different RNA segments that encode up to 
17 proteins; several of which are produced from a single segment (Vasin et al., 
2014). New proteins are continually being discovered, although not all of these 
proteins contribute to the infectious life cycle (figure 1b), nor are they found to be 
present in every virus subtype. Virus particles are pleomorphic, with the spherical 
forms having a diameter of ~100 nm and the filamentous forms often in excess of 
300 nm (Bouvier & Palese, 2008). 
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Figure 1. (a) Schematic structure and (b) life cycle of the influenza A virus. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews Microbiology (Shi, Wu, Zhang, 
Qi, & Gao, 2014), copyright (2014) https://www.nature.com/nrmicro/.  
 
The process of infection involves several stages, starting with the attachment protein 
haemaglutinin (HA) binding to sialic acid receptors on susceptible host cells such as 
epithelia of the upper respiratory tract. At this stage an antibody response against 
the HA antigen is usually activated in the host. Endocytosis occurs and the viral 
envelope merges into the membrane of the host cell allowing the nucleocapsid to 
become internalised in the cytoplasm (Cheung & Poon, 2007). The viral particle is 
held within endosomes where it is exposed to extremely acidic conditions. Prolonged 
acidification destroys the viral structure and triggers a large conformational change in 
the HA2 subunit causing them to expose hydrophobic fusion-promoting regions. 
Upon viral and endosomal membrane fusion, the proton channel formed by the M2 
protein is activated by the low pH and allows rapid transfer of hydrogen ions into the 
virus to facilitate uncoating of the capsid and dissociation of viral RNA (vRNA).  
The vRNA genome is then released into the cytoplasm in the form of 
ribonucleoprotein (RNP) complexes, which consist of vRNA segments wrapped 
around nucleoprotein (NP) monomers, with the end of each segment bound by the 
polymerase complex (figure 1a, bottom). The NP also maintains the RNP structure 
and is involved in many other processes such as intracellular trafficking of the viral 
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genome. From the cytoplasm, the vRNA segments translocate to the nucleus to be 
effectively transcribed into messenger RNA (mRNA) segments (Bouvier & Palese, 
2008).  
The influenza RNA dependent RNA polymerase (RdRp) composed of the three 
subunits: acidic polymerase (PA), polymerase basic protein 1 (PB1) and polymerase 
basic protein 2 (PB2) binds and cleaves capped host cell mRNA to use as a primer 
for viral mRNA synthesis. Positive-sense mRNA templates are produced for each 
segment and the viral mRNA is then translocated back into the cytoplasm in the form 
of RNP’s where it is translated into virus proteins. Some RNA is also retained in the 
nucleus as complementary RNA, from which the newly synthesised negative-sense 
vRNA is formed to be used as a template for further genome replication, which 
occurs in a primer independent manner. The process of nuclear export is mediated 
by the NEP and M1 proteins (Akarsu et al., 2003). 
The processed HA, NA and M2 surface proteins are transported and inserted in to 
the cell membrane, whilst the eight genomic segments are encapsidated by the NP, 
packaged and then enveloped using the host plasma membrane to form new virus 
particles. The virus finally buds from the infected cell and is released by sialidase 
enzyme activity of the NA approximately eight hours after infection (Bouvier & 
Palese, 2008; Couch, 1996). The influenza virus is notorious for replication errors, 
and if the cell is infected by two or more strains at the same time, random genetic re-
assortments, which lead to genomic diversity without impairing constituent protein 
functions. The process of viral genome replication disrupts normal host cell 
physiology and biochemistry, and is targeted by the immune system causing the 
characteristic symptoms of infection. The proteins of the influenza A virus are 
summarised in table 2, many of which are involved in the infectious life cycle and can 
be considered as potential antiviral drug targets. 
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Table 2. Proteins encoded by the 8 RNA genome segments of the influenza A virus and 
their major functions (Bouvier & Palese, 2008; Vasin et al., 2014).  
RNA 
segment 
Protein 
encoded 
Number of 
residues** 
Function 
1 PB2 759 Polymerase subunit: 5’ cap binding of host 
mRNA 
2 PB1 757 Initiates RNA synthesis, RNA elongation 
 PB1-F2* 
 
~90 Pro-apoptotic virulence factor, interacts with 
PB1 
 PB1-N40* 718 N-terminally truncated form of PB1, regulates 
PB1 and PB1-F2 expression 
3 PA 716 Cleavage of capped host mRNA 
 PA-N155* 568 Unknown (isoform of PA) 
 PA-N182* 535 Unknown (isoform of PA) 
 PA-X* 252 Modulates host response and virulence 
(isoform of PA) 
4 HA 550 Major antigen; attachment to sialic acid 
residues on host cells 
5 NP 498 Viral RNA binding, structural component of 
ribonucleoprotein complex, acts as adaptor 
between virus and host cells 
6 NA 470 Cleaves bonds between HA and sialic acid 
facilitating virus release from cell surfaces 
 
7 M1 252 Component of virion providing structural 
support, exports ribonucleoproteins 
 M2 97 Internal proton channel; virus uncoating 
 M42* 99 Can replace M2 in M2-null viruses 
8 NS1 219 Suppresses host interferon based antiviral 
immune response 
 NS2/NEP 121 Facilitates exit of viral RNA from the nucleus 
to cytoplasm 
 NS3* 174 Isoform of NS1 
*Recently discovered (since 2001), may not be present in all influenza A strains.  
**The number of residues for each protein varies between strains. 
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1.3 Current influenza A antivirals and documented resistance 
 
Although influenza infection is usually self-limiting, for high-risk patients or in case of 
highly pathogenic strains antiviral drug treatment is required. Two classes of antiviral 
drugs with specific activity targeting either the neuraminidase (NA) surface protein or 
the M2 proton channel are the first line of defence (figure 2). The NA inhibitors 
(Oseltamivir, Laninamivir, Peramivir and Zanamivir) block the enzymes active site 
which prevents cleavage of sialic acid residues on the surface of infected cells to 
stop the virus from spreading (Stiver, 2003). Whereas, the M2 inhibitors 
(adamantanes) obstruct the proton channel by interacting with the hydrophobic 
transmembrane domain of the M2 protein, thus preventing the entry of the viral 
genome into cells (Englund, 2002). 
 
Figure 2. Chemical structures of NA inhibitors (a) Oseltamivir, (b) Zanamivir, (c) Peramivir, 
and M2 inhibitors (d) Amantadine and (e) Rimantadine. All structures were obtained from the 
DrugBank database. 
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However, rapid amino acid mutation rates in these proteins and increasing 
emergence of widespread and subtype dependent antiviral drug resistance are 
concerning. Such examples of resistance include seasonal influenza A H1 strains 
harbouring the histidine to tyrosine substitution at position 274 (H274Y), conveying 
high level Oseltamivir resistance through partial displacement of Oseltamivir out of 
the NA binding site, corresponding to antiviral treatment failure (Hurt, Holien, Parker, 
& Barr, 2009; Moscona, 2009). Similarly, the affinity of drug binding is reduced by the 
S31N substitution in the transmembrane domain of the M2 protein (Schnell & Chou, 
2008) and due to extensive resistance, the adamantanes are no longer 
recommended for antiviral treatment (CDC, 2016). Several other amino acid point 
mutations in the NA and M2 proteins have also been found which are known to 
confer a resistant phenotype (Samson, Pizzorno, Abed, & Boivin, 2013;  Wang et al., 
2011). Furthermore, depending on the virus strain, these antiviral drugs may not 
work to the same extent due to differing levels in drug sensitivity. 
 
1.4 Recent discoveries of influenza A inhibitors 
 
Due to increasing reports of drug resistance, inhibitor molecules targeting proteins 
other than the M2 and NA are frequently being discovered through different 
approaches and experimentally evaluated by various methods (Naesens, Stevaert, & 
Vanderlinden, 2016). A number of NS1 protein antagonists such as NSC125044, 
JJ3297 and A22 were identified to reduce influenza replication using cell based 
assays, whilst other inhibitors have been found using functional biochemical assays 
(reviewed in Engel, 2013). Although the specific binding regions for many of these 
compounds to NS1 are unknown.  
The inhibitor Nucleozin identified from a cell based screening study was found to 
target the nucleoprotein or the viral RNP complex (Amorim, Kao, & Digard, 2013; 
Kao et al., 2010) and has shown inhibitory effects on virus replication in vitro. The 
small molecule Naproxen also targeting the NP was initially identified by virtual 
screening, followed by molecular dynamics simulation analysis, and verified by in 
vitro antiviral tests to show reduced viral titres (Lejal et al., 2013). The compound 
RK424, identified from screening a library of compounds using cell based replication 
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assays was also found to target the NP/RNP complex and reduced virus replication 
of several strains (Kakisaka et al., 2015).  
The viral polymerase is another popular antiviral target of interest; the purine analog 
Favipiravir (T-705) is a drug that targets the RNA polymerase, and phase three 
clinical trials have been completed in Japan (Furuta et al., 2013). The novel small 
molecule inhibitor ASN2 which was discovered from a high-throughput cell screening 
assay also targets the polymerase (presumably the PB1 subunit) and can inhibit 
replication of the major pandemic subtypes (Ortigoza et al., 2012). More recently, a 
compound targeting the PB1-PB2 interface named PP7 has been discovered and 
showed inhibitory effects on virus replication against H1N1, H7N9 and H9N2 
subtypes (Yuan et al., 2017). Overall, the number of potential influenza A replication 
inhibitors reported is steadily rising and there is increasing focus on investigating 
internal proteins as target sites for antiviral drugs (reviewed in Patel & Kukol, 
(2016b)). This is due to lower rates of evolution based on sequence and structure 
analysis (Warren, Wan, Conant, & Korkin, 2013).   
 
1.5 Evolutionary conserved ligand binding sites as antiviral targets 
 
Comparison of protein sequences enables similarities and differences at the level of 
individual amino acid residues to be analysed with the aim of inferring evolutionary 
relationships. Sequence relatedness often corresponds to the level of structural and 
functional conservation; therefore appreciating the evolution of influenza A protein 
sequences from all hosts and subtypes over time is essential for antiviral drug 
discovery. One common approach for this analysis is through multiple sequence 
alignment (Capra & Singh, 2007). Generally, residues displaying strict conservation 
are essential for correct protein folding, structure support and maintenance, as well 
as comprising binding interfaces and molecular recognition sites. Non-essential 
amino acids are usually more prone to mutation, with a minor influence on the viral 
fitness. However, a conservation study on the influenza acid polymerase protein has 
shown that residues classed as non-conserved may indeed be biologically important, 
and that functional residues are not always conserved (Wu et al., 2015). 
Sequence conservation data may be incorporated with structural information 
available for proteins in public databases, in addition to computationally predicted 
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models to identify and evaluate antiviral target sites as shown in this work. 
Previously, similar studies using this approach have identified novel binding sites for 
antivirals on the NS1 protein and nuclear export protein (Darapaneni, Prabhakar & 
Kukol, 2009), as well as the nucleoprotein (Kukol & Hughes, 2014). Building on this 
approach with the use of virtual screening and docking predictions, potential drug 
target sites and compounds can be further assessed. It is important that potential 
ligand binding sites are within or close to highly conserved amino acid regions as 
they are less likely to undergo genetic mutations which may render antiviral drugs 
targeting these sites ineffective (Kukol & Patel, 2014). 
 
1.6 Aims & Objectives 
 
To address the problem of influenza antiviral drug resistance, the reassortment of 
genomic segments from different host-type viruses, and the lack of effective drugs 
available, this research aimed to identify 1) highly conserved regions of selected 
internal influenza A viral proteins that overlap with predicted ligand binding sites and 
2) potential inhibitor molecules that may bind to those sites. 
These aims are addressed by drawing on the increased number of influenza virus 
genome sequences in comparison to earlier studies (Darapaneni, Prabhaker, & 
Kukol, 2009; Kukol & Hughes, 2014), as well as using an improved method of 
calculating sequence conservation and a more accurate method of predicting binding 
site locations. In addition, full-length protein structures are used with molecular 
dynamics simulations performed on the initial comparative models. Molecular 
docking based virtual screening is used to predict potential inhibitor molecules. 
Additional work presented in chapter six aimed to improve the accuracy of virtual 
screening and docking predictions by developing and evaluating a novel receptor-
decoy binding site strategy.  
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2 GENERAL MATERIALS & METHODS 
 
2.1 Materials 
 
Local computer workstations with Linux and Windows operating systems were used 
for bioinformatics and protein structure analysis. Molecular dynamics (MD) 
simulations were performed with Gromacs versions 4.5.5, 4.6.5 or 2016 (Hess, 
Kutzner, van der Spoel, & Lindahl, 2008; Pronk et al., 2013) on the University of 
Hertfordshire High Performance Computer cluster (UH-HPC). Graphs were produced 
with the plotting tool GRACE, using .xvg format files as input. Virtual screening was 
performed with AutoDock version 4.2 (Morris & Huey, 2009; Morris et al., 1998) and 
AutoDock Vina version 1.1.1 (Trott & Olson, 2010) with the help of Raccoon 
graphical user interface (Forli et al., 2016) on the UH-HPC and AutoDock Tools 
version 1.5.6. Protein structures, simulation trajectories and docking results were 
visualised with the molecular graphics viewers Rasmol (Sayle & Milner-White, 1995), 
Visual Molecular Dynamics (VMD) (Humphrey, Dalke, & Schulten, 1996), The PyMol 
Molecular Graphics System, version 1.7.4.5 Edu, Schrodinger, LLC and AutoDock 
Tools (Morris & Huey, 2009). Molecular interactions between proteins and ligands 
were identified with LigPlot+ version 1.4.5 (Laskowski & Swindells, 2011). 
 
2.2 Protein sequence analysis 
 
All protein sequences were downloaded from the National Centre for Biotechnology 
Information (NCBI) Influenza Virus Resource database (Bao et al., 2008). The 
Cluster Database at High Identity with Tolerance (CD-HIT) Suite web server  
(Huang, Niu, Gao, Fu, & Li, 2010) was used to remove redundancy of sequences 
based on a specified similarity threshold. Multiple sequence alignments were 
performed with the Clustal Omega web server version 1.2.1 or 1.2.3  (Sievers et al., 
2011). The default settings for all parameters remained unchanged whereby the 
mBed algorithm was used to generate the guide tree and the number of combined 
guide tree and Hidden Markov Model iterations remained at 0. The sequence 
alignment viewer and editor Jalview Version 2 (Waterhouse, Procter, Martin, Clamp, 
& Barton, 2009) and BioEdit version 7.2.3 (Hall, 1999) was used to analyse and edit 
the alignments. 
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2.3 Calculation of amino acid conservation 
 
From the multiple sequence alignment output file, the amino acid conservation was 
calculated using the Jalview AACons Web server (Waterhouse et al., 2009). The 
Valdar scoring method was selected for the calculation as it showed to be an 
accurate approach to quantify evolutionary conservation, described in a review 
evaluating 18 different scoring methods. The parameters considered in the 
calculation include amino acid frequency and stereo-chemical diversity with a full 
substitution matrix, as well as normalising against redundancy to reduce the effect of 
bias sampling and penalizing gaps (Valdar, 2002). The calculation produces a 
numerical score for each position in the alignment ranging between 0 (low 
conservation) and 1.0 (high conservation). To map the degree of amino acid 
conservation onto the protein structures with a colour scale and identify conserved 
residues within binding sites, the original conservation scores obtained from the 
Jalview web server were re-scaled between zero and one hundred (0 being high 
conservation and 100 being low conservation) using the following formula: 
 
New Score = (Vs – min) * (100/ (1- min))  
Where Vs is the original Valdar score, min is the minimum conservation score out of 
the dataset and 1 is the maximum conservation score. The values for the 
temperature-factors in a PDB file were then replaced with the re-scaled conservation 
scores for each amino acid. Thus, allowing the protein structure to be coloured by 
conservation according to a temperature gradient from blue (high conservation/cold) 
to red (low conservation/hot). 
 
 
 
 
 
 
25 
 
 
2.4 Protein modelling and molecular dynamics (MD) simulations 
 
Experimental structures of influenza proteins were obtained from the RCSB protein 
data bank (PDB) (www.rcsb.org). To account for incomplete or missing regions of 
structures, the Iterative Threading ASSembly Refinement (I-TASSER) server was 
used for 3D protein structure prediction (http://zhanglab.ccmb.med.umich.edu/I-
TASSER/). The server uses both template based and template free (ab-initio) 
methods to generate models and consistently performs well in the biennial 
community wide Critical Assessment of protein Structure Prediction (CASP) 
experiments (Yang & Zhang, 2015; Zhang, 2008). Experimental and model 
coordinates were combined to generate full length models. Energy minimisation was 
performed to remove atomic clashes from the models and to prepare the system for 
MD simulations. MD simulations provide a dynamic view of protein structure over 
time and have been used to improve models from structure prediction methods 
(Kalia & Kukol, 2011). The accuracy of MD simulations is dependent on the force 
field which is the combination of mathematical equations and parameters used to 
relate the chemical structure to energy based on atomic positions (Guvench & 
MacKerell, 2008). In this work simulations over 100 ns were performed to reveal 
conformational changes of the unrestrained regions of the protein models.  
 
2.4.1 Simulation analysis 
 
Simulation trajectories were analysed by calculating the root mean square deviation 
(RMSD) of backbone heavy atoms with respect to the starting structure using the 
Gromacs function ‘g_rms’. The RMSD is a measure of overall structural similarity 
between structures ‘1’ and ‘0’ and is calculated as follows: 
 
 
 
Where ri = (x,y,z) is the vector of the coordinates, N the number of atoms, M the 
relative mass of the molecule and mi the relative mass of each atom. A backbone 
RMSD of smaller than 0.2 nm is normally considered as small structural fluctuation; 
while an RMSD > 0.3 nm indicates a conformational change.  
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Cluster analysis was performed to find the most representative groups of protein 
structure conformations sampled during the simulations using the Gromacs function 
‘g_cluster’. The RMSD cut-off distance between structures to determine cluster 
membership and the fraction of the trajectory frames to analyse were determined 
from the RMSD plots. The gromos method for clustering was used. The central 
structure is the structure with the smallest average RMSD from all other structures 
within that cluster. The group selected for least squares fitting was backbone and the 
group for output was selected as protein.  
 
2.5 Prediction of binding hot spots 
 
Computational solvent mapping to identify potential ligand binding hot spots was 
performed using the FTMap web server (http://ftmap.bu.edu/) (Hall, Kozakov, & 
Vajda, 2012) for all influenza A proteins selected. The server requires a structure in 
PDB format to be uploaded and uses 16 different small organic molecules of varying 
properties, (ethanol, isopropanol, isobutanol, acetone, acetaldehyde, dimethyl ether, 
cyclohexane, ethane, acetonitrile, urea, methylamine, phenol, benzaldehyde, 
benzene, acetamide, and N,N dimethylformamide) as probes which are docked onto 
the protein surface to locate favourable binding hot spots. These hot spots are 
ranked based on their average binding free energy, and low energy sites where 
several different probe clusters overlap (consensus) are considered as potential 
ligand binding sites. In addition to locating binding hot spots, functional groups from 
the probes that interact favourably with the protein can be identified (Brenke et al., 
2009; Hall, Kozakov, & Vajda, 2012). The principle behind computational solvent 
mapping is shown in figure 3. 
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Figure 3. Principle of computational solvent mapping using two probes to identify ligand 
binding sites. The green circles and orange hexagons indicate a cluster for a molecular 
probe type. Where clusters overlap indicates the consensus site. Adapted by permission 
from Springer Nature: Springer, New York, NY, Computational Drug Discovery and Design, 
Hall et al., 2012, copyright (2012). 
 
2.6 Virtual Screening 
 
Virtual screening (VS) is a widely used technique in the field of medicinal chemistry 
to identify lead compounds from a chemically diverse library that can bind to a 
receptor. It is usually distinguished between ligand-based and receptor-based VS, 
with ligand-based VS requiring a number of known ligands to develop a 
pharmacophore model that is subsequently used to search a chemical library. In the 
present work the receptor based VS approach was followed that involves a process 
called molecular docking, which employs an algorithm to predict the best binding 
conformation of flexible small molecules to a specific protein receptor binding site 
(Kitchen, Decornez, Furr, & Bajorath, 2004). Three main stages are involved in the 
docking procedure: file preparation of the receptor, docking of the ligand through 
conformational and positional search and ligand scoring. The scoring and docking is 
often combined, as the scoring function is used to optimise the docking process, 
although external scoring functions can be applied afterwards. The scoring function 
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used in the docking software evaluates the binding free energy of docking 
configurations to reflect the strength of protein-ligand binding. The results from 
screening large chemical libraries can then be ranked and the conformations with 
highest negative binding energy are considered to portray the most favourable 
binding mode, however, these results must be treated with caution (Chen, 2015). 
The rank list can be filtered and assessed to appropriately select compounds for 
experimental testing.  
The factors that influence the outcome of a docking experiment include the 
biophysical interactions between protein and ligand on the one hand, namely, 
complementarity in size, shape, electrostatics, polarity and potential for hydrophobic, 
hydrogen bonding interactions between the ligand and receptor (Karthikeyan & Vyas, 
2014), and on the other hand the exhaustiveness of the conformational search and 
accuracy of the scoring function. An evaluation of three docking algorithms that are 
commonly used for virtual screening showed that AutoDock Vina was the best single 
method, while ligand prediction can be improved by combining the rank lists of 
AutoDock 4 and AutoDock Vina (Kukol, 2011). This consensus approach was 
therefore used for the NS1 protein and the NEP. 
 
2.6.1 Chemical compound library 
 
The National Cancer Insitute (NCI) Plated 2007 chemical compound library was 
downloaded from the ZINC database (http://zinc.docking.org/). This consisted of 3D 
structures of all molecules at pH 6-8 in .mol2 format. The file containing the codes of 
molecules at 80% similarity cut-off was also obtained from the ZINC database that 
applied clustering based on the Tanimoto coefficient using ChemAxon default 
fingerprints. These molecules were in the simplified molecular input line entry system 
format (.smi) which describes chemical structures in a linear format that can be 
interpreted by the computer. A script (appendix 9.5) was used to extract the 
molecules within the 80% similarity cut-off level from the NCI library to give a 
chemically diverse library. The extracted molecules were written to an output file in 
.mol2 format for virtual screening using the command: 
$ perl extract.pl result-80.smi nci_all.mol2 > output.mol2    
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The chemical compounds in .mol2 format were split into individual files and saved in 
the PDBQT format using the AutoDock screening preparation tool Raccoon to give a 
total of 52,172 compounds. The PDBQT format is an extension of the PDB format 
with the addition of atom charges and types added into the file. 
 
2.6.2 AutoDock 4 
 
AutoDock 4 is freely available software which performs docking based on a grid map 
method to describe the receptor protein and the Lamarckian Genetic Algorithm to 
iteratively select the lowest binding energy conformation of a ligand (Morris et al., 
2009). The AutoDock Tools software package (Morris & Huey, 2009) was used to 
define the 3D space for docking with a grid spacing of 0.375 Å to calculate box 
dimensions. A grid parameter file (.gpf) specifying the size and location of the 
docking grid and a docking parameter file (.dpf) specifying the input parameters for 
the AutoDock calculation must be written to perform the docking (appendix 9.6 and 
9.7). For all protein targets the number of energy evaluations was set to 350,000 and 
the population size was 150. The screening preparation tool Raccoon was used to 
prepare files; the interface consists of five tabs: Ligand(s), Receptor(s), Maps, 
Docking and VS Generation, which required input of the ligands and receptor files in 
PDBQT format, the .gpf to produce the grid maps for each atom type in the ligands, 
and the .dpf. The script used to perform the screening is shown in appendix 9.8. 
 
2.6.3 AutoDock Vina  
 
AutoDock Vina is also a freely available program for virtual screening and molecular 
docking. Although it has a similar name to AutoDock 4 it is a different program with 
higher speed and accuracy due to a different docking algorithm and scoring function 
implemented to predict binding modes (Trott & Olson, 2010). To perform the 
screening with AutoDock Vina, a configuration file was written which specified the 
input files and the docking box size which remained the same as that used with 
AutoDock 4. The script used to perform the screening is shown in appendix 9.9.  
To analyse the screening results, scripts were used to produce a rank list of binding 
affinities in kcal/mol from lowest to highest for each protein-ligand interaction from 
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the AutoDock Vina and AutoDock 4 output files, and to combine the AutoDock 4 and 
AutoDock Vina rank lists together (appendix 9.10). 
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3 THE NON-STRUCTURAL PROTEIN 1 (NS1) 
3.1 INTRODUCTION 
 
The influenza A non-structural protein 1 (figure 4) is a multifunctional protein 
encoded by the unspliced mRNA of genome segment eight. It is approximately 26 
kDa in weight and its most recognised function is counteracting the interferon (IFN) 
based host immune response via two molecular mechanisms: inhibiting activation of 
interferon regulatory factor 3 (IRF3) and therefore reducing IFN gene expression 
(Mibayashi et al., 2007; Talon et al., 2000), and inhibiting IFN pre-mRNA processing 
through binding CPSF30; although these functions are reported to be strain specific 
(Krug, 2015). Other important functions include binding poly A tails of cellular mRNA 
keeping them in the nucleus, and regulating viral RNA replication (Hale, Randall, 
Ortin, & Jackson, 2008). Previously, the NS1 protein was thought to be non-
structural, however, it has recently been identified at low levels within nascent virions 
and can therefore be considered a structural component of the virion (Hutchinson et 
al., 2014). The NS1 structure consists of an N-terminal RNA binding domain (RBD), 
and a C-terminal effector domain (ED) which is joined by a linker region (LR) (Lin, 
Lan, & Zhang, 2007), as shown in figure 4. A review by Hale (2014) states that NS1 
can be considered a structurally dynamic protein that forms various conformational 
states.  
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Figure 4. Cartoon representation of an NS1 protein model based on a H5N1 strain. The 
protein backbone is coloured showing the RBD in blue, LR in green and ED in red. 
 
3.1.1 Structure and function of the RNA binding domain (RBD) 
 
The RBD is made up of residues 1-73 which form three α-helices consisting of 
residues 4-24 (helix 1), 31-50 (helix 2) and 54-70 (helix 3) (Lin et al., 2007). The 
RBD facilitates the formation of NS1 homodimers in solution to recognise viral and 
cellular RNA molecules by interlocking three helices from one monomer with three 
helices from another monomer. It is reported that highly conserved basic residues 
such as Arg38 in helix two specifically interact through hydrogen bonding with the 
double stranded RNA backbone (Cheng, Wong, & Yuan, 2009). The linker region 
(LR) immediately following the RBD is made up of residues 74-88. The LR allows 
conformational changes of the RBD and ED and a recent crystallography study 
based on a H6N6 NS1 mutant revealed that a shortened LR, as well as residue 
identity at this position restricts the ability of the ED to adopt different positions 
relative to the RBD (Carrillo et al., 2014).  
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3.1.2 Structure and function of the effector domain (ED) 
 
The ED is made up of residues ~88-230 which form three α-helices and seven β-
strands (Bornholdt & Prasad, 2008). In this domain, six β–strands form an 
antiparallel twisted β-sheet around a long central α-helix and the structure is 
maintained through hydrophobic interactions between the twisted β-sheet and the α-
helix (Lin et al., 2007). The ED inhibits post-transcriptional processing of cellular pre-
mRNA by binding and inhibiting two cellular proteins: cleavage and polyadenylation 
specificity factor 30 (CPSF30), and poly (A) binding protein II (PABII). Residues 
between positions 144-188 bind two zinc finger regions of the CPSF30 protein which 
prevents the 3’ end processing of cellular pre-mRNA. This results in suppression of 
host antiviral mRNA expression, such as IFN-β, reducing the host immune response 
(Twu, Noah, Rao, Kuo, & Krug, 2006). The 215-230 region binds PABII, also 
resulting in nuclear accumulation of unprocessed 3' poly A tail pre-mRNAs (Chen, Li, 
& Krug, 1999; Tu et al., 2011), inhibiting export of host mRNA and cellular protein 
synthesis. 
The ED also binds protein kinase R (PKR) at the 123-127 region to deactivate the 
PKR pathway that would normally inhibit cellular and viral protein synthesis and 
consequently virus replication (Min, Li, Sen, & Krug, 2007). The C-terminal tail 
constitutes the last few residues of the ED and similar to the LR, varies in length 
depending on the strain (Carrillo et al., 2014). The changes in the length of the NS1 
protein may be due to mutations associated with stop codons. Overall, as the NS1 
ED contains several regions involved in protein binding that enhance virus survival; 
targeting these areas with drug-like compounds may inhibit key functions or protein 
interactions to influence virus replication. A study on NS1 conservation and binding 
site analysis has previously been done (Darapaneni et al., 2009), however, since 
2009 the number of available NS1 sequences has increased more than three times 
and alternative computational methods with improved accuracy for calculating 
conservation (Valdar, 2002) and binding site prediction have been identified that are 
employed in this project. Additionally, through virtual screening, potential replication 
inhibitors are predicted and subsequently evaluated in cell-culture. 
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3.2 COMPUTATIONAL METHODS 
 
3.2.1 NS1 sequence analysis  
 
The sequence analysis was performed according to general methods section 2.2. 
Briefly, full length NS1 sequences were chosen from all hosts, regions and subtypes 
until 2014. Identical sequences were removed. The CD-HIT web server (Huang, Niu, 
Gao, Fu & Li, 2010) was used to remove redundancy of the sequences at a similarity 
threshold of 98%. Global pairwise sequence alignment between the NS1 H5N1 
sequence A/Vietnam/1203/2004 used for protein modelling and the H1N1 sequence 
A/England/529/2013 of the strain used in experimental assays (gene sequence 
provided by Dr Angie Lackenby) was done using the EMBOSS Needle tool version 
6.6.0 (http://www.ebi.ac.uk/Tools/psa/emboss_needle/) with the default settings. For 
calculation of amino acid conservation see general methods section 2.3. The 
minimum score used for re-scaling was 0.480. Scores for the extra five residues of 
the linker region and the extended C-terminal tail were not included during re-
scaling. 
 
3.2.2 Protein modelling 
 
The full length H5N1 NS1 sequence (A/Vietnam/1203/2004) was submitted to the I-
TASSER modelling server (Zhang, 2008) to identify a suitable template covering the 
entire protein sequence, and to build a structure that accounted for missing residues: 
1-4, 75-79 and 198-215 in the PDB structure 3F5T. The RMSD between the I-
TASSER model and PDB structure was calculated to indicate the level of similarity 
between the two sets of atom coordinates. The final NS1 model was generated by 
copying the structural information of residues 1-5, 74-80, 197-215 from the I-
TASSER model into the PDB file of the experimental structure using a text editor. 
Missing side chains of Gln63 and Ile68 were reconstructed with Swiss-PDB Viewer 
version 4.1 (Guex & Peitsch, 1997). 
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3.2.3 Molecular dynamics simulations 
 
The starting structure in PDB format was converted to a Gromacs file and molecular 
topology file with the program pdb2gmx. The AMBER99SB – ILDN force field was 
selected as it demonstrated high accuracy in a systematic evaluation of eleven 
molecular dynamics force fields using Gromacs (Beauchamp, Lin, Das, & Pande, 
2012) along with the Transferable Intermolecular Potential 3 Point (TIP3P) water 
model. The protein was solvated in water in a cubic box with periodic boundary 
conditions to avoid edge effects at the boundary of the system. The charge of the 
chemical system was neutralised with four sodium ions and additional NaCl at 100 
mM concentration. The following commands were used (‘$’ identifies the command 
prompt): 
$ pdb2gmx -f ns1.pdb -o ns1.gro -p ns1.top -ter –ignh 
$ editconf -f ns1.gro -d 0.75 -o box.gro -bt cubic 
$ genbox -cp box.gro -cs spc216.gro -p ns1.top –o water.gro 
$ grompp -f ions.mdp –p ns1.top –c water.gro -o ions.tpr 
$ genion -s ions.tpr -neutral -conc 0.1 –p ns1.top -o ions.gro 
 
Energy minimisation with 500 steps of the steepest descent algorithm followed by 
200 ps MD simulation with position restraints on the protein non-hydrogen atoms 
was performed to equilibrate the system. The following commands were used: 
$ grompp -f em.mdp -p ns1.top -c ions.gro -o em.tpr 
$ mdrun -s em.tpr -c after_em.gro 
$ grompp -f posres.mdp -p ns1.top -c after_em.gro -o posres.tpr 
$ mdrun -s posres.tpr -c after_posresMD.gro -v >& posres.log & 
 
For the production run, three replicate partially position restrained simulations over 
100 ns (50 million steps) were performed. The position restraints were introduced to 
maintain the experimentally known structure, except the unknown C-terminus 
residues 196 to 215; therefore position restraints were gradually released as shown 
in table 3. The temperature of the system was set to remain constant at 300 K using 
the velocity rescaling thermostat with a coupling constant of 0.5 ps and pressure 
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coupling was set at 1.0 atm with the Parinello Rahman barostat. The Particle Mesh 
Ewald (PME) method for calculating electrostatic interactions was used and the 
simulation was performed at a time step of 2 fs. Coordinates were written to the 
output trajectory file every ten thousand steps. The implementation of position 
restraints was verified by analysing root mean square fluctuation (RMSF) for each 
residue using the Gromacs function ‘g_rmsf’. 
 
Table 3. Implementation of position restraint forces in the x, y, z axis on the non-hydrogen 
atoms of the NS1 protein. A force of 1000 indicates full restraint on an atom and 0 indicates 
full motion. 
Atoms Residue fx fy fz 
1-3081 1-195 1000 1000 1000 
3082-3101 196 500 500 500 
3102-3111 197 100 100 100 
3112-3159 198-199 1 1 1 
3160 onwards 200-215 0 0 0 
     
 
 
3.2.4 Prediction of binding hot spots 
 
Following cluster analysis, a central NS1 structure was selected for prediction of 
binding hot spots using FTMap. See general methods section 2.5.  
 
3.2.5 Virtual screening 
 
The screening was performed according to general methods section 2.6. The grid 
box dimensions for docking against the target site were set using AutoDock Tools as 
follows: 
center_x = -6.147 
center_y = 14.692 
center_z = -21.069 
size_x = 18.75 
size_y = 16.5 
size_z = 18.75 
 
The receptor-decoy method described in chapter 6 was applied for the NS1 protein 
as initial results from the evaluation showed that this method was able to improve 
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virtual screening predications. The grid box dimensions for the decoy site docking 
were set as follows: 
center_x = 4.217 
center_y = 5.529 
center_z = -22.353 
size_x = 15 
size_y = 13.5 
size_z = 18.75 
 
Molecules in the top 15% of the decoy site rank list were used to generate the 
adjusted binding site rank list. 
 
3.2.6 Potential drug target identification – PharmMapper  
 
Following experimental work (section 3.3), the PharmMapper web server 
(http://59.78.96.61/pharmmapper/) (Liu et al., 2010) was used to identify potential 
protein drug targets given a small molecule. The mol2 file for compound D was 
submitted to the server using the default settings with all target sets selected. The 
server uses a pharmacophore mapping approach to screen a database 
(PharmTargetDB) which consists of known pharmacophore models (a collection of 
molecular features that enable interactions between a receptor and ligand) to find the 
best pose and ‘fit score’ of a query molecule to a protein target (Liu et al., 2010).  
 
3.3 EXPERIMENTAL METHODS 
 
Based on results from the consensus virtual screening predictions, selected 
compounds were ordered from the Drug Synthesis and Chemistry Branch, 
Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, 
National Cancer Institute (NCI) (http://dtp.cancer.gov) for antiviral testing. These 
compounds are supplied without charge, except postage, to the scientific community. 
The following experiments involving virus culture were performed at the Respiratory 
Virus Unit, Public Health England, Colindale, according to standard operating 
procedures. 
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3.3.1 Influenza virus titration by plaque assay  
 
Plaque assays are used to determine the number of infectious viral particles in a 
sample. Therefore this assay was performed to determine the optimal virus dilution 
to infect the cell monolayer and produce a visible number of plaques for further 
antiviral experiments. The virus strain used for infection of cells was 
A/England/529/2013 (H1N1), which is a contemporary strain, sensitive to the 
neuraminidase inhibitor Oseltamivir carboxylate. 
 
3.3.1.1 Preparation of cells 
 
1 ml Madine-darby Canine Kidney-SIAT (MDCK-SIAT) cells in minimum essential 
media (MEM) with 10% Fetal Calf Serum were plated out into each well of a twelve 
well sterile flat bottomed tissue culture plate in triplicate. Plates were incubated for 
three days at 37°C with 5% CO2 to produce a confluent cell monolayer. 
 
3.3.1.2 Preparation of virus dilutions and inoculating cells 
 
A ten-fold dilution series from 10-1 to 10-7 was prepared by adding 100 µl of virus 
suspension to 900 µl of virus transport medium (VTM). 100 µl of this dilution was 
then transferred to 900 µl of VTM and the dilution series was continued in this 
manner up to 10-7. Growth medium was aspirated out of each well and the cell 
monolayer was washed twice with warmed, sterile phosphate buffer saline (PBS). To 
each well, 100 µl of the corresponding virus dilution was added; each dilution had 
duplicate wells. The virus was left to adsorb at room temperature for one hour. 
Plates were agitated gently every fifteen minutes to ensure an even distribution of 
the virus inoculum.   
 
3.3.1.3 Preparation of agar overlay 
 
10 ml aliquots of 2% MP Biomedicals Agarose were placed in a boiling water bath for 
fifteen minutes. The molten agar was then placed in a water bath at 45°C to cool 
before use. 1 ml of Gentamycin was added to 500 ml 2x Dulbecco’s Modified Eagle’s 
Media (DMEM) with Earles salts, 25 mM HEPES and Glutamax. 175 µl tolylsulfonyl 
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phenylalanine chloromethyl ketone (TPCK)-trypsin was added to 70 ml 2x DMEM to 
give a concentration of 1.25 µg/ml in the final agar overlay. 
The virus inoculum was aspirated from the highest dilution to the lowest. 10 ml of the 
prepared warmed medium was added to 10 ml molten agarose and mixed. 1 ml of 
the agar/MEM mix was added to each well of the plate. The plates were left to stand 
at room temperature for fifteen minutes to cool and set, and then incubated at 37˚C 
and 5% CO2 for 72 hours. 
 
3.3.1.4 Fixing and staining cells 
 
1 ml of 5% gluteraldehyde solution was added to each well and left at room 
temperature for a minimum of two hours to allow penetration through the agar. The 
excess gluteraldehyde was poured off and the agar was removed from each well by 
holding the plates in running water. 1 ml of 5% carbol fuchsin was added to each 
well to stain the cells. The stain was left for 30 minutes after which the excess carbol 
fuchsin was poured off. The plates were washed in running water to remove excess 
stain and blotted dry.  
 
3.3.1.5 Calculation of plaque forming units (PFU) 
 
The number of PFU/ml was calculated as follows:  
Mean plaque number x virus dilution x 10 
 
3.3.2 Influenza plaque reduction assay  
 
A number of laboratory methods to assess the susceptibility of influenza to antiviral 
drugs have been developed (Sidwell & Smee, 2000). The plaque reduction assay is 
considered to be the gold standard method for assessing the susceptibility of 
influenza to antiviral compounds (Hayden, Cote, & Douglas, 1980; Zambon, 1998). 
The assay is based on assessing changes in plaque morphology (size and/or 
number) in the presence of an antiviral compound. The final result is usually 
expressed as a fold reduction in susceptibility to a drug compared to a reference 
40 
 
 
virus control. However, it is not always possible to calculate an IC50 (50% inhibitory 
concentration) value using this assay. 
From the results of the standard plaque assay, the virus dilution used for infection of 
the cell monolayer was x10-4. The standard plaque assay using this dilution (with no 
drug) was also performed alongside each plaque reduction assay. 4.5 mg of 
compounds in table 6 were dissolved in Dimethyl Sulfoxide (DMSO) with heating to 
an initial stock concentration of 10 mM. 4.0 mg of compound H was dissolved in 
100% ethyl acetate to an initial stock concentration of 10 mM.  
   
3.3.2.1 Preparation and inoculation of cells 
 
Cells were prepared as described in section 3.3.1.1. For the inoculation, 100 µl of 
virus was added to eleven wells, and 100 µl of VTM was added to the twelfth well 
(cell control). The virus was left to adsorb at room temperature for one hour. Plates 
were agitated gently every fifteen minutes to ensure an even distribution of the virus 
inoculum. An extra plate with six wells for virus controls, and six wells of media 
containing 1% DMSO as a cell control (no virus) was also prepared. A 1% DMSO 
concentration in 2x DMEM was tested as a cell control to assess the effect of DMSO 
with a 100 µM drug concentration. 
 
3.3.2.2 Preparation of overlay and drug titration 
 
Agar was prepared as described in section 3.3.1.3. 1 ml of Gentamycin was added 
to 500 ml 2x Dulbecco’s Modified Eagle’s Media (DMEM) with Earles salts, 25 mM 
HEPES and Glutamax. 500 µl DMSO was added to the media to give a final DMSO 
concentration of 0.1% in the assay. Starting with an initial concentration of 200 µM 
compound in warmed media, a ten-fold titration described in table 4 was performed.  
A ten-fold titration was also performed with Oseltamivir carboxylate for use as a 
positive control in the assay. 3.75 µl trypsin was added to each drug dilution to give a 
concentration of 1.25 µg/ml in the final agar overlay. 
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Table 4. Preparation of ten-fold drug dilutions for the plaque reduction assay. 
Step Dilution series Concentration 
(µM) 
In assay concentration 
(µM) 
1 30 µl of 10 mM compound 
+ 1470 µl 2x media  
200 100 
2 150 µl of step 1 + 1350 µl 
2x media 
20 10 
3 150 µl of step 2 + 1350 µl 
2x media 
2 1 
4 150 µl of step 3 + 1350 µl 
2x media 
0.2 0.1 
5 150 µl of step 4 + 1350 µl 
2x media 
0.02 0.01 
 
3.3.2.3 Removal of inoculum and addition of overlay 
 
The inoculum was removed from all wells except the virus control and cell control 
wells. 1.5 ml of molten agarose was added to 1.5 ml of the appropriate media 
containing compound and then added to the corresponding wells in duplicate (figure 
5). The inoculum was then removed from the virus control and cell control wells and 
1.5 ml 2x DMEM/agar mix was added. The plates were left to stand at room 
temperature for fifteen minutes to cool and set, and then incubated at 37˚C and 5% 
CO2 for 72 hours.  
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Figure 5. Layout of a twelve well plate overlaid with a ten-fold drug dilution series in 
duplicate for assessing plaque reduction. 
 
3.3.2.4 Fixing and staining cells 
 
Cells were fixed and stained as described in section 3.3.1.4. 
 
3.3.3 Drug Affinity Responsive Target Stability (DARTS) 
 
To determine if a compound had bound to the NS1 protein, the DARTS method was 
performed. This method is based on the concept that when a small molecule 
compound binds to a protein, the target protein structure becomes more stable and 
more resistant to degradation by proteases than the protein without the bound 
compound (figure 6). The extent of proteolysis can then be analysed by Western 
Blotting. The advantage of this method is that it can be performed using complex 
protein mixtures, without requiring purified proteins (Lomenick et al., 2009; 
Lomenick, Jung, Wohlschlegel, & Huang, 2011).  
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Figure 6. Diagram of the DARTS method for drug target identification. Figure adapted from 
(Lomenick et al., 2009, 2011). Reproduced with permission of the Licensor through PLSclear 
from Current Protocols in Chemical Biology, John Wiley & Sons Limited, copyright (2011). 
 
3.3.3.1 Collecting and lysing cells 
 
1 ml MDCK-SIAT cells were seeded in a twelve well tissue culture plate and 
incubated for three days at 37°C with 5% CO2 to produce a confluent cell monolayer. 
The growth media was aspirated and washed twice with phosphate buffered saline 
(PBS). 100 µl of virus (A/Eng/529/2013) was inoculated into each well. The virus was 
left to adsorb at room temperature for one hour. Plates were agitated gently every 
fifteen minutes to ensure an even distribution of the virus inoculum. The inoculum 
was removed and 1 ml of serum free DMEM with 12.5 µg/ml of TPCK trypsin was 
added to each well. The cells were incubated at 37°C with 5% CO2 for 24 hours. 
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To confirm viral replication, the virus titer from 50 µl of the supernatant of each well 
was determined by haemagglutination assay. The supernatants were then removed 
from each well and cell monolayers were washed once with PBS. 100 µl of 1x 
NuPAge lithium dodecyl sulphate (LDS) sample buffer (Thermo Fisher Scientific) 
was added to each well and left for ten minutes at room temperature. The cells were 
scraped off each well into the sample buffer. The buffer/cell mixture was heated at 
95°C for five minutes and microfuged for 20 seconds.  
 
3.3.3.2 Protein-small molecule incubation 
 
3 µl dithiothreitol (DTT) reducing agent was added to 600 µl of the LDS sample 
buffer/cell lysate and heated at 80˚C for five minutes. The lysate was split into two 
samples (297 µl each). 3 µl DMSO was added to one sample and 3 µl small 
molecule (compound D) was added at 1 mM concentration to give a final 
concentration of 10 µM for a 1:100 dilution. The samples were mixed immediately by 
gentle flicking several times and microfuged briefly. The samples were incubated at 
room temperature for one hour. 
 
3.3.3.3 Proteolysis 
 
10 mg/ml Pronase stock solution was diluted to 1.25 mg/ml by mixing 12.5 µl 
Pronase with 87.5 µl cold 1x TNC buffer. This served as the 1:100 Pronase stock 
solution. This was diluted by mixing with 1x TNC buffer to create 1:300, 1:1000, 
1:3000 and 1:10000 Pronase stock solutions. 
Five 50 µl aliquots from both protein samples were prepared and the remaining 50 µl 
was saved as a non-digested control sample. 2 µl 1:100 Pronase solution was added 
to one aliquot of compound treated sample, mixed and incubated at room 
temperature. Exactly one minute after starting the first digestion, 2 µl 1:100 Pronase 
solution was added to one aliquot of the DMSO sample, mixed and incubated at 
room temperature. The eight remaining aliquots were digested at one minute 
intervals in this manner. After 30 minutes, the digestion of the first aliquot was 
stopped by adding 3 µl cold 20x Protease inhibitor solution, mixing and placing on 
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ice. The remaining digestions were also stopped in the order they were started in 
one minute intervals.  
 
3.3.3.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE)  
 
SDS-PAGE is a common method for separation of protein mixtures by their 
molecular mass. 10 µl of the non-digested sample and each digested sample 
(compound treated and DMSO treated) were loaded and separated on a 15% 
polyacrylamide gel. 12 µl of biotinylated protein ladder (Cell Signalling Technology, 
#7727) was loaded alongside the samples as a molecular weight reference. The 
electrophoresis was run at 200V (constant voltage) for 40 minutes. 
 
3.3.3.5 Western Blotting 
 
Following SDS-PAGE, the gel was rinsed in blotting buffer for 15 minutes to remove 
salts and detergents. A polyvinylidene difluoride (PVDF) membrane was soaked in 
methanol for 15 seconds, then water for two minutes, followed by blotting buffer for 
15 minutes. The gel was transferred onto the PVDF membrane by wet blotting and 
the transfer was carried out at 200mA for 1 hour 45 minutes. The PVDF membrane 
was washed in 20 ml blocking solution (2% Tween 80 in PBS with 5% milk powder) 
for forty five minutes with shaking at room temperature. The membrane was then 
incubated in 15 ml of this blocking solution with addition of the influenza A virus NS1 
primary polyclonal antibody (Thermo Fisher Scientifc, #PA5-32243) at a 1:2000 
dilution at 4˚C overnight with shaking.  
The membrane was washed four times every five minutes in washing solution (PBS-
Tween x1) with shaking to remove traces of any free primary antibody. The 
membrane was then incubated in 10 ml of washing solution with addition of the 
secondary antibody (Goat anti-rabbit IgG HRP conjugated, Thermo Fisher Scientifc) 
at a 1:1000 dilution, and a HRP conjugated anti-biotin antibody at a 1:1000 dilution to 
detect the biotinylated protein ladder for one hour at room temperature with shaking. 
The membrane was washed again four times every five minutes in washing solution 
with shaking to remove unbound antibodies. 
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3.3.3.6 Enhanced Chemiluminescence (ECL) detection 
 
Equal volumes of reagent 1 and reagent 2 (PierceTM ECL Western Blotting 
Substrate, Thermo Fisher Scientific) were mixed together, added to the membrane 
and left to incubate for five minutes at room temperature. The protein blot was 
captured using the myECL Imager (Thermo Fisher Scientific).  
 
3.4 RESULTS 
 
3.4.1 NS1 amino acid conservation 
 
8426 NS1 protein sequences mainly from human and avian hosts from all 
geographic regions were initially obtained from the NCBI Influenza Virus Resource 
database (Bao et al., 2008). Applying a similarity threshold of 98%, the redundancy 
was reduced with CD-HIT. Sequences with non-standard residues were removed 
resulting in 1416 remaining sequences. In this work, the H5N1 A/Vietnam/1203/2004 
sequence numbering convention has been used where the five amino acid deletion 
is not included. This deletion found in several sequences was accounted for by the 
insertion of a gap region in the alignment.  
The Valdar conservation scores ranged from 0.480 (lowest) at position 215 to 1.0 
(highest) with Pro31, Asp115 and Ala127 being 100% conserved. The alignment 
profile showed that the majority of NS1 sequences had a high level of conservation 
in certain areas of the RNA binding domain and effector domain. This includes 
regions from Ile112-Lys121, and Leu142-Ser160, which both form beta sheets and 
loops on the effector domain. Regions of intermediate or low conservation (<0.850) 
include positions 21, 22, 25, 26, 60, 48, 73-79 (linker region), 107, 166, 201 and 212 
onwards (C-terminal tail). Amino acid substitutions observed for low conservation 
residues include E, G, D, A, V, I and S at position 60 and G, A, T, D, N, Y, S, R, K 
and I at position 166. The Valdar conservation scores for each amino acid position 
are presented in table 18 (appendix 9.1). The re-scaled scores were mapped to the 
NS1 structure for display purposes as shown in figure 7.  
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Figure 7. NS1 amino acid conservation mapped onto the protein structure. Blue regions 
indicate high conservation and red regions indicate low conservation (see colour scale). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
 
3.4.2 Protein modelling and MD simulations 
 
The I-TASSER server generated a full length NS1 model based on the H5N1 input 
sequence. Regions of the structure that were not sufficiently similar to any template 
were modelled ab-initio by the I-TASSER method (Zhang, 2008). The I-TASSER 
model and PDB experimental structure were somewhat different; in particular the 
side chain locations. The RMSD between backbone atoms was 0.87 Å, between all 
atoms 1.70 Å, and between side chains: 2.26 Å. Therefore the final NS1 model was 
produced by copying the structural information of residues 1-5, 74-80 and 197-215 
from the I-TASSER model into the PDB file of the experimental structure. 
From three repeats of 100 ns simulation trajectories and cluster analysis of the whole 
protein, it was observed that the conformation of the C-terminus (Trp198-Arg215) 
changed from the initial I-TASSER model; the experimentally known parts of the 
structure were kept fixed in space during the simulation. The first simulation 
produced three clusters of structures with cluster one being dominant, the second 
simulation produced one cluster, and the third simulation produced two clusters. The 
backbone RMSD for each simulation and the central structures from the cluster 
analysis are shown in figures 8-10 with the unrestrained part shown in blue. The 
structure from simulation two (figure 9b) was the final structure accepted for further 
analysis as it represented a large number of structures. Also, upon visual inspection 
it was the most similar to the structure in cluster one from simulation three and the 
structure in cluster two from simulation one. 
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Figure 8. (a) RMSD plot of protein backbone coordinates for simulation one over 100 ns. For 
clustering analysis the trajectory was analysed from 20,000 ps. The RMSD cut-off was set at 
0.2 nm. (b) C-terminus conformation (blue) of the central structure from cluster one 
representing 96% of the analysed trajectory. (c) C-terminus conformation (blue) of the 
central structure from cluster two representing 3.7% of the analysed trajectory. (d) C-
terminus conformation of the central structure from cluster three representing 0.32% of the 
analysed trajectory.  
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Figure 9. (a) RMSD plot of protein backbone coordinates for simulation two over 100 ns. For 
clustering analysis the trajectory was analysed from 35,000 ps. The RMSD cut-off was set at 
0.15 nm. (b) C-terminus conformation (blue) of the central structure from cluster one 
representing 100% of the analysed trajectory. 
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Figure 10. (a) RMSD plot of protein backbone coordinates for simulation three over 100 ns. 
For clustering analysis the trajectory was analysed from 40,000 ps. The RMSD cut-off was 
set at 0.1 nm. (b) C-terminus conformation (blue) of the central structure from cluster one 
representing 99.9% of the analysed trajectory. (c) C-terminus conformation (blue) of the 
central structure from cluster two representing 0.07% of the analysed trajectory.  
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3.4.3 Computational solvent mapping 
 
Sixteen potential binding hot spots were identified through computational solvent 
mapping using the FTMap server. FTMap assigned the hot spots in clusters based 
on the number of different molecular probes binding to the site and ranked 
accordingly, with the highest ranked site, ‘site one’, binding with the largest number 
of different probes. The top ten binding sites were found to be located in different 
regions of the effector domain. Only sites fourteen and fifteen were located on the 
RNA binding domain. Several sites were located close together such as one and six, 
two and three, and seven and eleven. All hot spots were close to the surface of the 
protein. The level of residue conservation together with the top ten binding site 
locations is shown in figure 11. A distance of 4.0 Å was chosen to indicate the amino 
acid residues surrounding the top five hot spots (table 5). It was decided to consider 
binding sites one and six as a larger consensus site and subject it to virtual 
screening as this region is highly conserved and also composed of residues known 
to interact with host cell proteins.  
 
 
Table 5. NS1 amino acid residues within 4.0 Å of the five highest ranked binding sites 
predicted by FTMap. 
Site Number of 
probes bound 
Residues within 4.0 Å of binding site 
1 13 Trp97, Phe98, Leu100, Asp115, Ile118, Val152 
2 9 Leu139, Ile140, Pro157, Pro159 
3 10 Met93, Ser94, Ile140, Leu141 
4 10 Arg135, Arg195, Asn200, Pro210 
5 9 Ile155, Gly174, Ile177, Gly178, Glu181 
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Figure 11. Ligand binding sites identified and ranked by the FTMap solvent mapping 
algorithm (green) and degree of conservation shown together on the NS1 structure. Blue 
regions indicate high conservation and red regions indicate low conservation (see colour 
scale). 
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3.4.4 Virtual screening 
 
The results of the binding affinities for ~52,000 molecules docked against the NS1 
target site using AutoDock 4 ranged from –10.9 kcal/mol to +2.7 kcal/mol, and -10.3 
kcal/mol to -1.7 kcal/mol using AutoDock Vina. For the decoy site screening, the 
binding affinities using AutoDock 4 ranged from –7.5 kcal/mol to +357.3 kcal/mol, 
and from -7.1 kcal/mol to +28.8 kcal/mol using AutoDock Vina. The binding site rank 
lists were adjusted based on the top 15% of molecules in the decoy site rank list and 
then combined using the script in appendix 9.10.  
Fifteen molecules from the combined rank list were selected based on binding 
affinity and Lipinski’s rule of five, which state that drug like compounds should ideally 
display the following properties (Lipinski, Lombardo, Dominy, & Feeney, 2001): 
 Molecular mass less than 500 Daltons 
 High lipophilicity (expressed as LogP less than five) 
 Less than five hydrogen bond donors 
 Less than ten hydrogen bond acceptors 
The chemical structures and properties of the top fifteen compounds selected and 
ordered for experimental testing are presented in table 6. The compounds were re-
named alphabetically as indicated by the letters in brackets preceding the ZINC 
code. Common amino acid residues of the NS1 protein involved in binding these 
molecules identified using the software LigPlot+ (Laskowski & Swindells, 2011) 
include Phe98, Leu100, Asp115, Ala150 and Ile151, which are all well conserved. 
Docking models between four of the selected top molecules are shown in figure 12 
and molecular interactions with compound I are shown in figure 13. 
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Table 6. Chemical structures of the top 15 compounds selected from the virtual screening 
based on binding affinity (ΔG), number of Hydrogen bond donors (H Don) and acceptors (H 
Acc), molecular weight and partition coefficient (xLogP) obtained from the ZINC database. 
Compound                              
(ZINC ID) 
ΔG 
(kcal/mol) 
H Don H Acc Mol Wt 
(g/mol) 
xLogP 
(A) ZINC01646194 
 
-8.50 
 
0 
 
3 
 
345 
 
3.75 
(B) ZINC16998207 
 
-8.40 
 
2 
 
4 
 
316 
 
3.50 
(C) ZINC01669818 
 
-8.10 
 
2 
 
3 
 
317 
 
5.60 
 
 
 
 
 
(D) ZINC04769085 
 
-8.0 
 
1 
 
3 
 
325 
 
4.98 
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Compound                              
(ZINC ID) 
ΔG (kcal/mol) H Don H Acc Mol Wt 
(g/mol) 
xLogP 
(E) ZINC00344361 
 
-7.90 
 
0 
 
4 
 
342 
 
4.83 
(F) ZINC01566093    
 
-7.70 
 
 
1 
 
4 
 
370 
 
4.60 
(G) ZINC17002748 
 
-8.90 
 
0 
 
3 
 
362 
 
4.34 
 
(H) ZINC01760393 
 
-8.80 
 
2 
 
4 
 
395 
 
5.22 
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Compound (ZINC ID) ΔG (kcal/mol) H Don H Acc Mol Wt 
(g/mol) 
xLogP 
(I) ZINC13281542 
 
-8.60 
 
2 
 
4 
 
391 
 
5.56 
 
(L) ZINC05479272 
 
-8.50 
 
2 
 
4 
 
338 
 
3.80 
(K) ZINC06761478 
 
-8.49 
 
0 
 
4 
 
353 
 
4.64 
(O) ZINC01625245 
 
-8.40 
 
0 
 
6 
 
363 
 
3.63 
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Compound (ZINC ID) ΔG (kcal/mol) H Don H Acc Mol Wt 
(g/mol) 
xLogP  
(J) ZINC01650972 
 
-8.50 
 
1 
 
8 
 
405 
 
2.78 
(N) ZINC01580219 
 
-8.40 
 
1 
 
8 
 
404 
 
 
1.86 
 
 
 
 
 
 
(M) ZINC01703250 
 
-8.44 
 
2 
 
6 
 
418 
 
3.85 
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Figure 12. Models of four predicted top hit compounds (A, F, M, I) docked to the target site 
of the NS1 protein. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  Molecular interactions between compound I and amino acid residues of the NS1 
target site after docking with AutoDock 4. 
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3.4.5 Plaque assay 
 
The virus dilution resulting in a countable number or visible plaques in the MDCK-
SIAT cell line was x10-4, and the mean number of plaques at this dilution was 81. 
The number of plaque forming units per ml (PFU/ml) at this dilution was calculated 
as: 81 x 104 x 10 = 8.1x106 PFU/ml. 
 
3.4.6 Plaque reduction assay 
 
Compounds I, L and M failed to dissolve in water, 100% DMSO, 100% ethyl acetate 
and 100% ethanol, and therefore were not tested in vitro. The average PFU/ml in 
cells treated with 0.1% DMSO and infected with a x10-4 virus dilution was calculated 
as: ~112 x 104 x 10 = ~1.12x107 PFU/ml by standard plaque assay, although this 
varied slightly between each assay. 
The staining of the cell control (0.1% DMSO treated) showed that the cells had 
lasted under the experimental conditions over the five day period. The plaque 
morphology at each drug concentration was compared by visual observation to the 
virus control at day three post infection. Results for Oseltamivir carboxylate (positive 
control, figure 14) showed a distinct reduction in plaque size with increased drug 
concentration in each run, confirming that the assay was working, with the lowest 
concentration to reduce the plaque size by 50% being 0.1 µM. Out of the twelve 
remaining test compounds, most showed no success at changing plaque 
morphology and inhibiting virus replication. Several compounds (A, C, D, E, F and G) 
were toxic to the cell monolayer at 100 µM concentration. 
However, compound D (figure 15) and K (figure 16) did show a reduction in plaque 
size at different concentrations. (Refer to figure 5 for plate layout). Compound D 
showed a weak inhibitory effect at 10 µm, 1.0 µM, 0.1 µM and 0.01 µM. Compound K 
showed inhibition between 100 µM and 10 µM, therefore was also tested with a two-
fold dilution from 100 µM to 6.25 µM to narrow down the most effective inhibitory 
concentration; although it was observed that the change in plaque size was very 
similar at each intermediate concentration.    
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Figure 14.  Plaque reduction analysis of Oseltamivir carboxylate on MDCK-SIAT cells 
infected with influenza A/Eng/529/2013 under agar overlay. A ten-fold drug dilution series 
was overlaid in duplicate from 100 µM to 0.01 µM (following the green arrow) and the bottom 
left well of each duplicate shows the controls (without drug). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Plaque reduction analysis of compound D on MDCK-SIAT cells infected with 
influenza A/Eng/529/2013 under agar overlay. A ten-fold drug dilution series was overlaid in 
duplicate from 100 µM to 0.01 µM (following the green arrow) and the bottom left well of 
each duplicate shows the controls (without drug). 
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Figure 16. Plaque reduction analysis of compound K on MDCK-SIAT cells infected with 
influenza A/Eng/529/2013 under agar overlay. (a) Ten-fold drug dilution overlaid in duplicate 
from 100 µM to 0.01 µM (b) Two-fold drug dilution overlaid in duplicate from 100 µM to 6.25 
µM (following the green arrow) and the bottom left well of each duplicate shows the controls 
(without drug). 
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3.4.7 H5N1 and H1N1 sequence alignment 
 
The pairwise sequence alignment between the H5N1 sequence used for molecular 
modelling and the H1N1 sequence used for antiviral experiments is shown in figure 
17. The two sequences (both isolated from humans) are not identical and differ by 49 
amino acids. The overall percent identity between the two sequences is 78% and the 
overall percent similarity is 88% calculated using the EBLOSUM62 matrix. Most 
notably, the H1N1 sequence does not have the five amino acid deletion (T, I, A, S, 
V) at position 80 in the linker region, unlike the H5N1 sequence. Several amino acids 
which were predicted to interact with the top hit molecules (e.g Leu105, Asp120, 
Ala155) are identical between the two sequences. 
 
Figure 17. NS1 human H5N1 (A/Vietnam/1203/2004) and human H1N1 
(A/England/529/2013) pairwise sequence alignment output. A vertical line indicates positions 
which have a single fully conserved residue, a colon indicates strongly similar properties and 
a period indicates weakly similar properties. (Ala at position 38 and 41 of the H5N1 
sequence is mismatched to Arg38 and Lys41 in the Uniprot sequence).  
 
 
 
 
64 
 
 
3.4.8 Drug Affinity Responsive Target Stability (DARTS) 
 
The binding of compound D at a concentration of 10 µM to the NS1 protein was 
tested based on the ability of compound D to stabilise NS1 against limited 
proteolysis. The proteolysis results using three different pronase concentrations 
(diluted from a starting concentration of 1.25 mg/ml) are shown on the western blot in 
figure 18. The strong bands produced at 26 kDa confirm presence of the NS1 protein 
in the cell lysate. At the highest pronase dilution of 1:10000, there is more proteolysis 
in the sample with the addition of the drug compound D (lane 3) than with DMSO 
vehicle control (lane 7). The detection of bands shows that the DARTS method is 
unable to confirm that compound D binds to the NS1 protein.   
  
 
Figure 18. Western blot showing the amount of influenza A NS1 proteolysis using three 
different pronase concentrations after incubation with drug compound D and with DMSO as 
vehicle control. 
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3.4.9 Potential drug target identification - PharmMapper 
 
As the DARTS method was unable to confirm binding of compound D to the NS1 
protein, it was tested, if compound D is predicted to bind to any other drug target for 
which pharmacophore models are available. The top five pharmacophore models 
identified by the PharmMapper web server are shown in table 7. The top target 
identified (sorted by Z-score) was bacteriorhodopsin which interacts through 
hydrophobic interactions with compound D.  
 
Table 7. PharmMapper results showing five top hit pharmacophore models predicted and 
their feature interactions. 
Rank Target Name PDB ID Z-score No. 
hydrophobic 
No. HB 
acc 
No. HB 
donors 
1 Bacteriorhodopsin 1P8U 3.24 7 0 0 
2 Vanillyl-alcohol 
oxidase 
 
1W1J 2.51 2 2 0 
3 Heat shock protein 
HSP 90-alpha 
1YC1 2.07 2 3 2 
4 Thyroid hormone 
receptor beta 
1N46 2.02 4 1 1 
5 Thyroid hormone 
receptor beta 
1NAX 2.01 4 1 1 
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3.5 DISCUSSION 
 
3.5.1 NS1 conservation  
 
The degree of NS1 protein conservation was determined from sequence data from 
all hosts and subtypes until 2014. The protein is highly conserved, as over 85% of 
residues had a conservation score of 0.800 or above based on the Valdar scores 
obtained from the multiple sequence alignment. The RNA binding domain (RBD) is a 
well conserved region, with helices one and two consisting of highly conserved 
residues; while positions 55, 56, 59 and 60 of helix three display intermediate or low 
conservation. Also, a short stretch of less conserved residues between positions 21-
26 form the loop region connecting helix 1 and 2. Regions on the effector domain 
such as the nuclear export signal region (residues 133-145 (Tynell, Melén, & 
Julkunen, 2014)) were highly conserved with scores >0.800, as well as Trp182 with a 
score of 0.998 which is most likely related to its importance for ED homodimerisation 
(Ayllon, Russell, García-Sastre, & Hale, 2012).   
The large variability in residue composition, and length of the C-terminal tail and 
linker region, which is frequently reported in literature (Hale et al., 2010; Tu et al., 
2011) was observed from the sequence alignment. Regions of low conservation may 
indicate that residues at that position do not play a significant role in the proteins 
overall function. Alternatively, major differences between sequences may result in 
changes in protein structure or biological functions. An example of this is the 205-
237 variable region, where sequences with extended C-terminal tails are able to bind 
the poly A binding protein II (PABPII) causing nuclear accumulation of cellular RNA 
(Chen et al., 1999), although this interaction is probably not essential for the overall 
viral life cycle, especially as many sequences display C-terminal truncations. 
Regarding the linker region, it is known that structural changes in domain orientation 
result from the variability of the residues present as well as determining NS1 
subcellular localisation (Li, Noah, & Noah, 2011).  
Compared to previous conservation analysis (Darapaneni et al., 2009), the results 
also show that despite the inclusion of many more protein sequences (~6000), the 
overall pattern of NS1 conservation is generally quite similar. Additionally, the 
different scoring method used in the current work to quantify conservation from a 
67 
 
 
sequence alignment influences the classification into conserved or variable residues, 
which is seen with a small number of residues in this analysis. 
 
3.5.2 Predicted binding hot spots 
 
Sixteen binding hot spots were predicted using FTMap, many of which were in 
conserved areas of the NS1 protein structure, with the top ten being located on the 
effector domain (ED).  Compared to the RNA binding domain, this domain is known 
to interact with many different cellular proteins, therefore it is expected to have more 
binding sites. The clustered hot spots are all surface accessible, which facilitates 
ligand binding. On the effector domain, binding site four and eight were shown to be 
spatially close together (within 5.0 Å), as well as sites five, seven and eleven.  
Hot spots one, five, six and twelve consist of residues 144-186 that were reported to 
interact with the cellular host protein CPSF30 (Twu et al., 2006). A later structural 
study of the ED based on the crystal structure from a H3N2 subtype (A/Udorn/72) 
defined the F2F3 domains of the CPSF30 binding pocket to be made up of residues 
Lys110, Ile117, Ile119, Glu121, Val180, Gly183, Gly184 and the highly conserved 
Trp187 (Das et al., 2008). Furthermore, the highly conserved Ile64 located on the 
RBD has recently been identified to interact with CPSF30 and its mutation to Thr64 
(which occurs rarely) decreases this interaction (DeDiego, Nogales, Lambert-Emo, 
Martinez-Sobrido, & Topham, 2016). The biological consequence of a ligand binding 
to these residues may prevent the inhibitory activity on host pre-mRNA processing. 
Although some of these residues including Trp187 (position 182 in the H5N1 
A/Vietnam/2004 sequence) which prominently protrudes from the protein and is 
required for ED dimer formation (Ayllon et al., 2012; Carrillo et al., 2014) were not 
close to any predicted binding sites. 
Also, the highly conserved glutamic acid residues at positions 91 and 92 which form 
the TRIM25 binding domain required for suppressing interleukin-1β secretion were 
not found to be close to any predicted binding sites (Gack et al., 2009; Moriyama et 
al., 2016), whilst site two, three and four neighbour residues between positions 123-
144 which may interact with the host protein hGBP1, which has a role in 
antagonising antiviral activity (Zhu et al., 2013). Site ten and eleven are located 
closest to the flexible and variable C-terminal region of the protein. Due to the high 
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conservation and rank assigned by the FTMap server, site one and six were selected 
as the target site for virtual screening.  
 
3.5.3 Top hit compounds and antiviral activity 
 
The consensus virtual screening and docking predictions showed that a large 
number of compounds have high predicted binding affinities to the NS1 target site. 
However, many of these may be false positive predictions (Chen, 2015). The 
docking conformations based on the output coordinate files enabled critical residues 
which directly participate in molecular interactions to be identified. Some of the top 
compounds shown in table 6 were predicted to interact with Phe98, Leu100, Asp115, 
Ile118, Lys121, Glu148, Ala150 and Ile151, all of which are well conserved. These 
interactions may involve, hydrogen bonding, hydrophobic interactions and ionic 
interactions.  
The plaque reduction assay, which is a broad phenotypic assay suitable for use 
when virus-drug target interactions are unknown, was performed to screen and 
determine the effect on influenza A replication after incubation with a compound at 
five different concentrations. Two out of twelve compounds tested (D and K) showed 
capability of reducing H1N1 virus replication at non-cytotoxic concentrations. This is 
a successful hit rate and is comparable with other experimental screening studies 
previously reported, such as the identification of six possible NS1 binding inhibitors 
from an initial screen of 446 small molecules after development of a fluorescence 
polarisation-based high throughput screening assay (Cho et al., 2012), and the 
discovery of four compounds out of an initial screen of ~2000 that showed influenza 
antiviral activity, which are thought to suppress NS1 function (Basu et al., 2009). The 
virtual screening approach in this work also presents the advantage of saving costs 
compared to using experimental screening methods.  
The remaining ten compounds showed no significant visible effect, although it is 
possible that these compounds and compound K, may still bind to NS1, albeit with 
no overall antiviral mechanism of action. Additionally, it has been shown with the 
example of PB2 inhibitors that the antiviral activity of the inhibitor compound may 
depend on the bioassay used (Stevaert & Naesens, 2016).  
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The binding of compound D to the NS1 protein was investigated with the DARTS 
method, that is based on the assumption that binding of a ligand protects the protein 
from proteolysis (Lomenick et al., 2011). The results indicate that the experiment 
was conducted successfully, as the primary antibody was able to detect the NS1 
protein and proteolysis had occurred at different pronase concentrations as shown 
on the Western blot (figure 18). However, the DARTS method did not show that the 
NS1 protein was protected from proteolysis by compound D, even under limited 
proteolysis conditions. The Western blot indicated that a similar level or even more 
proteolysis had occurred in the sample incubated with the drug, compared to the 
sample without. This could be because compound D does not bind to NS1, the 
concentration of compound D may have been too low, or that binding of compound D 
does not increase the stability of NS1 to protect it from proteolysis, hence the 
detection of protein bands below 26 kDa. 
A computational drug target prediction with PharmMapper showed that compound D 
does not bind major cellular target proteins, but it has the potential to bind to 
hydrophobic parts of transmembrane proteins such as bacteriorhodopsin. It may 
even interact with multiple targets. This may be an alternative explanation of the 
antiviral activity and it is possible that compound D probably binds to and inhibits a 
different influenza A protein, such as the transmembrane M2 protein, or 
haemagglutinin that is essential for the membrane fusion process. Overall, the 
results showed that through experimental testing of twelve compounds following 
virtual screening of ~50k compounds, an active inhibitor could be identified, although 
the predicted mechanism of action could not be confirmed. Additionally, the choice of 
compounds for testing is challenging as compounds with ideal drug like properties 
and strong binding affinity may not be compatible with cellular uptake.   
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4 THE NUCLEAR EXPORT PROTEIN (NEP) 
4.1 INTRODUCTION 
 
The nuclear export protein (formerly known as the non-structural protein 2 or NS2) is 
encoded by RNA segment eight and is 121 amino acid residues long. In the virion it 
is present bound to the M1 matrix protein through interaction with the prominently 
surface exposed residue Trp78. This interaction facilitates the main function of the 
NEP which is to export newly synthesized viral ribonucleoproteins (vRNPs) from the 
nucleus to the cytoplasm of infected cells to allow translation of mRNA into the 
structural proteins, as well as packaging the genome into progeny virions (Akarsu et 
al., 2003). This is an essential process during the replication cycle and is mediated 
by binding with the cellular export molecule chromosome region maintenance protein 
1 (CRM1) and its cofactor ranGTP (Neumann, Hughes, & Kawaoka, 2000). A model 
of vRNP export mediated by the NEP is shown in figure 19. 
Many other key functions of the NEP have also been found, such as regulating 
accumulation of viral RNA during transcription and translation (Robb, Smith, Vreede, 
& Fodor, 2009), interacting with cellular molecules such as ATPase to assist with 
viral budding (Paterson & Fodor, 2012) and several nucleoporins to enable 
nucleocytoplasmic transport (Chen, Huang, & Chen, 2010; O’Neill, Talon, & Palese, 
1998). The NEP has been found to be phosphorylated in infected cells (Richardson 
& Akkina, 1991), and the phosphoacceptor site(s) may be required for regulating 
nuclear export of vRNPs and/or polymerase activity (Reuther, Giese, Gotz, Riegger, 
& Schwemmle, 2014). 
Previous work reporting structural information for the NEP have suggested that the 
protein consisting of four helices adapts a compact, yet flexible and highly mobile 
conformation, in particular the N-terminal fragment consisting of residues 1-53 
(Darapaneni et al., 2009; Lommer & Luo, 2002). To date, there is only one 
experimentally determined structure available in the PDB (ID: 1PD3) for the NEP at a 
resolution of 2.6 Å (Akarsu et al., 2003). Furthermore, the N-terminal residues 1-62 
did not crystallise, which strongly indicates structural disorder (Le Gall, Romero, 
Cortese, Uversky, & Dunker, 2007). The N-terminus is recognised by the nuclear 
export machinery during replication and contains a leucine rich nuclear export signal 
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(NES) formed by residues 11-23 (O’Neill et al., 1998). Ser17 and Leu21 in this 
region were found to be highly conserved upon large scale sequence analysis and 
are therefore proposed to be key residues of the NES (Darapaneni et al., 2009). A 
second NES in a leucine rich region between residues 22 and 45 has also been 
identified and is proposed to be involved in the export of vRNPs (Huang et al., 2013).  
In contrast, the C-terminal region for which atom coordinates are available (Akarsu et 
al., 2003), is highly structured in the form of two co-linear α-helices and consists of 
several hydrophobic residues (Paterson & Fodor, 2012). The polymerase enhancing 
function of NEP has been shown to reside in the C-terminus (Reuther, Giese, Götz, 
et al., 2014). Unlike many of the other influenza A proteins, there have been no 
inhibitors identified which specifically target the NEP.  
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Model for NEP-mediated nuclear export of influenza viral ribonucleoproteins. The 
nuclear export signal of the NEP N-terminal domain is recognised by the cellular Crm1-
RanGTP complex, whilst the C-terminal domain is bound to the viral M1 protein to facilitate 
translocation of vRNP’s towards the cytoplasm. Figure reproduced from Paterson & Fodor 
(2012).  
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4.2 METHODS 
 
4.2.1 NEP sequence analysis 
 
The sequence analysis was performed according to general methods section 2.2. 
Briefly, full length NEP sequences were chosen from all hosts, regions and subtypes 
until September 2015. Identical sequences and sequences containing non-standard 
residues were removed. The CD-HIT web server (Huang et al., 2010) was used to 
remove redundancy of the sequences at a similarity threshold of 98%. For 
calculation of amino acid conservation see general methods section 2.3. The 
minimum score used for re-scaling was 0.632. 
 
4.2.2 Protein modelling 
 
The crystal structure of the NEP M1 binding domain (PDB ID 1PD3) from a H1N1 
sequence (A/Puerto Rico/8/1934) contained missing regions 1-62 at the N-terminus 
and 117-121 at the C-terminus. Therefore the I-TASSER server (Zhang, 2008) was 
used to generate a full model of this sequence. The I-TASSER model and chain A of 
the experimental structure 1PD3 were aligned by structural superposition in the 
protein structure viewer PyMol using the ‘align’ command and the coordinates of the 
alignment were saved as a PDB file. This PDB file was then modified to replace the 
structural information of residues 64-115 of the model with the experimentally known 
coordinates of 1PD3 using a text editor. Atom coordinates for residues 86 and 104 
from the model were not replaced.   
 
4.2.3 Molecular dynamics simulations 
 
Coordinates of the full length NEP model were used for MD simulations using 
Gromacs 2016. The starting structure was converted to a Gromacs file and 
molecular topology file with the program pdb2gmx. The AMBER99SB – ILDN force 
field was selected as it demonstrated high accuracy in a systematic evaluation of 
eleven MD force fields (Beauchamp et al., 2012) along with the TIP3P water model. 
The protein was solvated in explicit water in a cubic box with periodic boundary 
conditions, and the charge of the chemical system was neutralised with five sodium 
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ions and additional NaCl at 100 mM concentration. The following commands were 
used: 
 
$ gmx_mpi pdb2gmx -f myNEP_2.pdb -o NEP.gro -p NEP.top -ter –ignh 
$ gmx_mpi editconf -f NEP.gro -d 0.75 -o box.gro -bt cubic 
$ gmx_mpi solvate -cp box.gro -cs spc216.gro -p NEP.top -o solvated.gro 
$ gmx_mpi grompp -f ions.mdp -p NEP.top -c solvated.gro -o ions.tpr 
$ gmx_mpi genion -s ions.tpr -neutral -conc 0.1 -p NEP.top -o ions.gro 
 
Energy minimisation with 500 steps of the steepest descent algorithm followed by 
100 ps MD simulation with position restraints on the protein non-hydrogen atoms 
were performed to equilibrate the system.  The temperature of the system was set to 
remain constant at 300 K using the velocity rescaling thermostat with a coupling 
constant of 0.5 ps and pressure coupling was set at 1.0 atm with the Berendsen 
barostat. The Particle Mesh Ewald (PME) algorithm for calculating electrostatic 
interactions was used with the real space cut-off set at 1.0 nm with the Verlet cut-off 
scheme.  The following commands were used: 
$ gmx_mpi grompp -f em.mdp -p NEP.top -c ions.gro -o em1.tpr 
$ gmx_mpi mdrun -ntomp 4 -s em1.tpr -c nepAfterEM.gro 
$ gmx_mpi grompp -f posres.mdp -p NEP.top -c nepAfterEM.gro -o posresEq.tpr 
$ gmx_mpi mdrun -ntomp 4 -s posresEq.tpr -c nepAfterPosResEqMD.gro -v >& 
posres.log 
 
For the production run, three replicate partially position restrained simulations over 
100 ns (50 million steps) were performed. The same settings for equilibration were 
used, except the Parinello-Rahman barostat was used for pressure coupling and 
position restraints were released on N-terminus residues 1-65 by modifying the 
forces in the posre.itp file as shown in table 8. The simulations were performed at a 
time step of 2 fs. Coordinates were written to the compressed output trajectory file 
every ten thousand steps. The following commands were used: 
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$ gmx_mpi grompp –f partfree_md.mdp –p NEP.top –c nepAfterPosResEqMD.gro –t 
state.cpt –o Sim1.tpr 
$ gmx_mpi mdrun -s Sim1.tpr -c afterMD.gro -v -stepout 2000 
 
Table 8. Implementation of position restraint forces in the x, y, z axis on the non-hydrogen 
atoms of the NEP protein. A force of 1000 indicates full restraint on an atom and 0 indicates 
full motion. 
Atoms  Residue fx fy fz 
1-971 1-62 0 0 0 
972-1032 63-65 500  500 500 
1033 onwards 66 -121 1000 1000 1000 
 
 
Simulation trajectories were analysed by creating an index file specifying backbone 
atoms for residues 1-65 to calculate the root mean square deviation for the 
unrestrained part of the protein using the Gromacs function ‘rms’. The 
implementation of position restraints was verified by analysing the root mean square 
fluctuation for each residue using the Gromacs function ‘rmsf’. For cluster analysis 
the group selected for least squares fitting and RMSD calculation was residues 1-65, 
and the group for output was selected as protein.   
 
4.2.4 Prediction of intrinsic disorder 
 
A top ranking intrinsic disorder prediction server DISOPRED3 
(http://bioinf.cs.ucl.ac.uk/psipred/?disopred=1) was used to predict any intrinsically 
disordered regions for the NEP structure. The server is based on pattern recognition 
of an amino acid sequence against disordered regions in the PDB (Jones & 
Cozzetto, 2015; Ward, McGuffin, Bryson, Buxton, & Jones, 2004). The full H1N1 
sequence A/Puerto Rico/8/1934 used for modelling was entered as the input 
sequence. 
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4.2.5 Prediction of binding hot spots 
 
Following cluster analysis of the three MD trajectories, the central structures from the 
largest simulation clusters were selected for solvent mapping to predict binding hot 
spots. See general methods section 2.5. 
 
4.2.6 Virtual Screening 
 
A binding hot spot predicted in the same location between helix two and four on each 
NEP structure following cluster analysis was selected as the target site for virtual 
screening. The grid box parameters for docking using AutoDock Vina and AutoDock 
4 were set using AutoDock Tools as follows, with a grid spacing of 0.375 Å: 
center_x = 11.756 
center_y = 5.141 
center_z = -0.693 
size_x = 15.75 
size_y = 16.5 
size_z = 14.25 
exhaustiveness = 12 
 
The same NCI compound library used for screening against the NS1 protein was 
filtered using the software Open Babel version 2.3.1 (O’Boyle et al., 2011) to 
eliminate compounds with molecular weight over 500 g/mol and predicted logP over 
five using the command: 
$ obabel output.mol2 --filter “MW<500 logP<5” –O filtered.mol2     
The library was converted to SDF format using Open Babel to be passed through the 
Pan Assay Interference Compounds (PAINS) filter with the online FAF-Drugs3 (Free 
ADME-Tox Filtering Tool) program to identify and remove compounds that appear as 
frequent hitters in screening experiments (Baell & Holloway, 2010; Lagorce, 
Sperandio, Baell, Miteva, & Villoutreix, 2015). The filtered library was converted back 
to .mol2 format and compounds were split into individual ligand files in PDBQT 
format using the AutoDock screening preparation tool Raccoon. The DrugBank-
approved compound library (version 4.0) containing 1738 drugs between pH 6 and 8 
(Law et al., 2014) was downloaded from the ZINC database and also screened 
against the NEP target site in order to find any drugs which have been approved that 
may also target the NEP.  
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4.3 RESULTS 
4.3.1 NEP amino acid conservation 
 
3000 NEP sequences mainly from human, swine and avian hosts from all 
geographic regions were initially obtained from the NCBI Influenza Virus Resource 
(Bao et al., 2008). Applying a similarity threshold of 98% the redundancy was 
reduced with CD-HIT resulting in 889 sequences remaining. Clustal Omega was 
used to align the sequences and the alignment profile showed that sequences had a 
high level of conservation. The conservation scores for each amino acid based on 
Valdar’s scoring method are presented in table 19 (appendix 9.2) and ranged from 
0.632 at position 89 (lowest) to 1 (highest). Gly30, Leu38 and Arg66 were 100% 
conserved, whilst other highly conserved residues (>0.900) include Met16, Ser17, 
Tyr41, Leu69, Arg84 and Leu103. The most conserved region is from Thr90 to 
Glu110 which forms helix four at the C-terminus. The least conserved residues 
(<0.750) were found to be: Leu14, Glu22, Gly26, Ser57, Asn60, Glu63 and Ile89; 
several of these residues form the interhelical loops and turns between the helices. 
Frequent amino acid substitutions observed for positions displaying low conservation 
include E, M, R, Q, K, R, V, T and A at position 14, and K, T, V, I, N, L, A, S and T at 
position 89. For display purposes the scores were re-scaled and mapped onto the 
NEP structure shown in figure 20. 
 
 
 
 
 
 
 
 
 
 
Figure 20. NEP conservation mapped onto the NEP structure. Blue regions indicate high 
conservation and red regions indicate low conservation. 
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4.3.2 Protein modelling and MD simulations 
 
The I-TASSER server generated a full length NEP model based on the H1N1 input 
sequence. The C-terminal part of the experimental structure 1PD3 was used as the 
template and the remaining structure was modelled ab-initio as no suitable template 
was available. The RMSD between the C-terminal region of the model and 1PD3 
was 1.98 Å, indicating a small difference between the two structures. The 
experimentally known coordinates of 1PD3 chain A (C-terminal residues 64-115) 
were combined with the N-terminal part of the I-TASSER model to generate a model 
consisting of four parallel helices linked by three turns (figure 21). This model was 
used as the starting structure for molecular dynamics simulations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Model of the influenza A nuclear export protein with helices numbered. Regions 
modelled by I-TASSER are shown in blue.  
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From three 100 ns simulation trajectories and cluster analysis, it was observed that 
the conformation of the N-terminal (1-65) did not change significantly from the initial 
model; the experimentally known parts of the structure were kept restrained to their 
positions during the simulation. The backbone RMSD for the unrestrained part of the 
NEP from each simulation is shown in figure 22 for each simulation. Based on the 
RMSD plots, the trajectories were analysed to identify clusters of structures sampled 
starting from 10 ns with an RMSD cut-off of 0.2 nm. Simulation one produced eight 
clusters, simulation two produced nine clusters and simulation three produced ten 
clusters. The central structures from cluster one, which was the largest cluster from 
each simulation were within 3.0 Å of each other. The RMSF of N-terminal residues 
was also analysed (figure 23) and the most flexible residues were found to be 
between positions 22-27 and 53-57. 
 
 
Figure 22.  Root mean square deviation of NEP backbone atoms of residues 1-65 for three 
replicate 100 ns simulations, relative to the starting structure.   
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Figure 23. Root mean square fluctuation of NEP residues during three 100 ns simulations. 
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4.3.3 Intrinsic disorder prediction 
 
Disorder prediction was performed using DISOPRED3. The intrinsic disorder profile 
(figure 24) shows that the predicted NEP structure based on the H1N1 sequence is 
unlikely to be disordered. The N-terminal half shows more disorder than the C-
terminal half and possible disorder is indicated at residues Met1 and Asp2. A protein 
binding site was predicted within the disordered region indicating possible disorder to 
order transition upon protein binding. 
 
Figure 24. Intrinsic disorder profile for the nuclear export protein predicted from the 
sequence A/Puerto Rico/8/1934.  
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4.3.4 Computational solvent mapping 
 
The representative structures from the largest cluster from each simulation were 
uploaded to FTMap to identify potential binding hot spot locations. Common hot 
spots in the hydrophobic region between helix two and four were predicted for all 
three structures, although with different ranks assigned. The level of residue 
conservation together with hot spot locations is shown in figures 25-27. A distance of 
4.0 Å was chosen to indicate the amino acid residues surrounding the top five ligand 
binding spots (table 9-11).  
Ten hot spots were identified in different regions on the structure from simulation one 
(figure 25) with three hot spots (ranked first, second and fourth) located between 
helices two and four. Three spots were predicted between helix one and two. No 
spots were located in the loop regions connecting helices one and two or helices 
three and four. All spots are surface exposed and the top five are closely surrounded 
by residues of high or intermediate conservation. Spot one, two and four bind with 
the highest number of different FTMap probe types.  
Ten hot spots were identified on the structure from simulation two (figure 26). Five 
spots were located in the space between helix two and four, including spots eight 
and nine, and three and ten which were clustered closely together. All hot spots are 
surface exposed. Hot spot six is in the loop region between helix one and two and is 
surrounded by residues at position 20-29 that display high fluctuation. This spot is 
also very close to the highly variable residue Gly26.  
Nine hot spots were identified on the structure from simulation three, all of which are 
surface accessible (figure 27). Spots one and four are located in the space between 
helix two and four, and are closely surrounded by highly conserved residues. Spot 
two is between helix one and three on the opposite side of the protein and close to 
Leu14 which is highly variable. No spots were located in the loop regions that join 
helix one and two, and three and four. The location of hot spot two from structure 
one was common amongst all three structures, and in a conserved region therefore 
was selected as the target site for virtual screening. 
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Figure 25. Ligand binding hot spots (green) identified by FTMap shown together with the 
degree of NEP conservation for the structure from simulation 1. The numbers indicate the 
site rank assigned by the algorithm. 
 
Table 9. NEP amino acid residues within 4.0 Å of the five highest ranked binding hot spots 
predicted by FTMap from simulation 1. Highly conserved residues are shown in bold face. 
Site No. of probes bound Residues within 4.0 Å of binding site 
1   15 Met52, Val49, Phe116, Leu120, Asn62, Ile113, 
Ser117, Arg66, Trp65  
2  15 Arg42, Asp43, Gly46, Phe73, Val109, Leu105, 
Leu106 
3  13 Gln20, Met19, Arg15, Ile12, Leu21, Tyr41, Met16, 
Ser37  
4  15 Val109, Met50, Gly46, Val49, Phe116, Glu112, 
Ile113  
5  12 Asn4, Thr5, Ser7, Ser8, Phe9, Ile12, Tyr41, Leu40, 
Ser44  
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Figure 26. Ligand binding hot spots (green) identified by FTMap shown together with the 
degree of NEP conservation for the structure from simulation 2. The numbers indicate the 
site rank assigned by the algorithm. 
 
 
Table 10. NEP amino acid residues within 4.0 Å of the five highest ranked binding hot spots 
predicted by FTMap from simulation 2. Highly conserved residues are shown in bold face. 
Site Number of probes bound Residues within 4.0 Å of binding site 
1   13 Arg114, Glu67, Ser117, Glu110, Glu63, Gln71, 
Arg66, Ile113, Gly70  
2  13 Lys39, Arg42, Leu105,  Leu106,  Ala102,  Val109, 
Ile80  
3  11 Val49, Met50, Met52, Gly53, Phe116,  Ser117, 
Leu120, Arg66, Ile113, Trp65 
4  12 Met1, Gln68,  Lys64, Arg61, Val6,  Met52  
5  10 Met19, Tyr41, Arg15, Ile12, Met16 
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Figure 27. Ligand binding hot spots (green) identified by FTMap shown together with the 
degree of NEP conservation for the structure from simulation 3. The numbers indicate the 
site rank assigned by the algorithm. 
 
Table 11. NEP amino acid residues within 4.0 Å of the five highest ranked binding hot spots 
predicted by FTMap from simulation 3. Highly conserved residues are shown in bold face. 
Site Number of probes bound Residues within 4.0 Å of binding site 
1   15 Arg42, Val109, Gly46,  Val49, Met50, Glu47,  
Phe116, Glu112, Ile113  
2   16 Leu14,  Glu82, Trp78, Ser17, Gln10,  Glu75, Leu13, 
Leu79  
3   14 Met50, Met52, Asn62, His56, Trp65, Gly53 
4   12 Lys39, Arg42, Asp43, Ala102, Leu103, Leu105, 
Leu106, Ile80 
5   11 Leu40, Ile12, Ser44, Tyr41, Ser37  
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4.3.5 Virtual screening  
 
The predicted binding affinities for 42,348 molecules from the NCI library ranged 
from -8.95 kcal/mol to +20.63 kcal/mol using AutoDock 4 (figure 28). The majority of 
compounds were found to bind within the range of -4.0 kcal/mol and -5.0 kcal/mol 
and 46 compounds had a positive binding energy score. The predicted binding 
affinities ranged from -8.7 kcal/mol to +34.9 kcal/mol using AutoDock Vina (figure 
29). The majority of compounds were found to bind within the range of -4.5 kcal/mol 
and -5.5 kcal/mol and 17 compounds had a positive binding energy score. Several of 
the same compounds were identified with positive scores using both software.  
The AutoDock Vina and AutoDock 4 rank lists were combined and the properties of 
ten top compounds from the consensus rank list are presented in table 12. Common 
amino acid residues involved in binding some of these compounds through hydrogen 
bonding and hydrophobic interactions identified using LigPlot+ include Arg42, Asp43, 
Lys39, Ile80, Gln101, Leu105, Val109; all of which are highly conserved. The 
compound ZINC01717023 was identified as a top hit molecule with the most similar 
binding scores from both software. The docking model of compound ZINC01509994 
in the NEP target site, as well as predicted interactions is shown in figure 32. 
1738 compounds from the DrugBank-approved library were also screened against 
the same NEP target site. The binding affinities ranged from -8.31 kcal/mol to +22.59 
kcal/mol using AutoDock 4 (figure 30) and from -7.7 kcal/mol to +7.4 kcal/mol using 
AutoDock Vina (figure 31). 29 drugs had a positive binding score with Autodock 4 
compared to 2 drugs with AutoDock Vina (not included in the binding score 
distribution graphs). None of the approved drugs had a significantly stronger 
predicted binding affinity than the top ranked compound of the NCI library. The top 
ranked drug from the consensus rank list was found to be the steroid nandrolone 
phenylpropionate (ZINC03881613).  
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Figure 28. Frequency distribution plot of the binding affinities for ligands screened using 
AutoDock 4 from the NCI library. Negative scores shown only. 
 
 
Figure 29. Frequency distribution plot of the binding affinities for all ligands screened using 
AutoDock Vina from the NCI library. Negative scores shown only. 
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Figure 30. Frequency distribution plot of the binding affinities for drugs from the DrugBank 
library screened using AutoDock 4.  
 
Figure 31. Frequency distribution plot of the binding affinities for drugs from the DrugBank 
library screened using AutoDock Vina.  
0
50
100
150
200
250
300
0 -0.5 -1 -1.5 -2 -2.5 -3 -3.5 -4 -4.5 -5 -5.5 -6 -6.5 -7 -7.5 -8 -8.5
N
u
m
b
e
r 
o
f 
d
ru
g
s
Binding affinity (kcal/mol)
0
50
100
150
200
250
300
350
400
450
0 -0.5 -1 -1.5 -2 -2.5 -3 -3.5 -4 -4.5 -5 -5.5 -6 -6.5 -7 -7.5 -8
N
u
m
b
e
r 
o
f 
d
ru
g
s
Binding affinity (kcal/mol)
88 
 
 
Table 12. Properties of top compounds from the NCI and DrugBank libraries identified by 
consensus virtual screening based on binding affinity (ΔG), number of Hydrogen bond 
donors (H Don) and acceptors (H Acc), molecular weight and partition coefficent (xLogP) at 
pH 7 from the ZINC database. 
Compound (ZINC ID) ΔG (kcal/mol) xLogP H Don H Acc Mol Wt (g/mol) 
 AD4 Vina     
NCI library       
ZINC01564229 -8.95 -7.4 -3.26 0 2 360.460 
ZINC01717023 -8.09 -8.7 5.29 0 5 417.420 
ZINC01509994 -8.52 -7.6 4.31 0 9 436.646 
ZINC02035101 -6.9 -8.3 3.48 0 5 357.365 
ZINC01592475 -8.10 -6.5 1.63 0 8 345.283 
ZINC01646246 -7.34 -8.2 5.62 0 2 332.358 
ZINC01717021 -7.07 -8.2 5.29 0 5 417.420 
ZINC01561925 -8.02 -7.5 5.53 0 6 406.444 
ZINC08617587 -7.93 -6.2 4.21 0 1 270.416 
ZINC01645196 -7.83 -6.6 3.57 2 7 405.892 
DrugBank library       
Nandrolone 
phenylpropionate 
-6.83 -7.7 5.51 0 3 406.566 
Estropipate -8.3 -7.1 0.84 0 5 349.428 
Pimozide -4.56 -7.6 5.62 2 4 462.564 
Tretinoin -7.8 -6.0 5.80 0 2 299.434 
Ergotamine tartrate -6.28 -7.6 2.08 3 10 581.673 
Adapalene -7.5 -6.6 7.69 0 3 411.521 
Azelastine 
Hydrochloride 
-6.88 -7.5 4.82 1 4 382.915 
Tasosartan -7.50 -7.1 2.48 0 8 410.461 
Azelastine 
hydrochloride 
-6.84 -7.5 4.82 1 4 382.915 
Zuclopenthixol -7.33 -6.4 4.69 2 3 401.983 
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Figure 32. 3D docking model of compound ZINC01509994 in the NEP target site predicted 
with AutoDock 4 in blue and Vina in green (top) and 2D plot showing molecular interactions 
from the AutoDock 4 pose, green dash lines represent hydrogen bonds (bottom). 
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4.4 DISCUSSION 
 
4.4.1 NEP conservation 
 
Conservation results show that the influenza A nuclear export protein (NEP) is highly 
conserved as 112 out of 121 amino acid residues scored above 0.800 based on the 
Valdar conservation scores from the sequence alignment. The most conserved 
region with several residues scoring over 0.950 was the C-terminal helix four, which 
has been reported to stabilise the structure of helix three by interacting with the M1 
protein through intermolecular bonds between side chains (Akarsu et al., 2003). 
Gly30, Leu38 and Arg66 were found to be 100% conserved and could therefore be 
most resistant to change due to evolutionary adaption of the virus.  In comparison to 
previous research by Darapaneni, Prabhakar and Kukol (2009), the results 
presented here also show that the inclusion of many more protein sequences and 
the use of a different scoring method to quantify conservation do have an influence 
on conservation classification. This is seen with residues Ser23, Met31, Lys39, 
Asp47, Phe58, Glu67, Leu107, Phe116, and Phe118, which were reported as 
variable in the previous study, but were found to be highly conserved in this work. 
Despite these exceptions, the overall pattern of conservation is otherwise similar.  
With regards to known NEP functions, the N-terminal region is reported to contain 
two leucine rich nuclear export signal (NES) motifs at position 11-21 and 22-45 
(Huang et al., 2013). In this work, the second NES region was found to consist of 
four highly conserved leucine residues at position 21, 28, 38 and 45. This feature 
assists recognition and binding of cellular CRM1-RanGTP to the NES (Akarsu et al., 
2003) and is a critical stage in transport of vRNPs out of the nucleus. Furthermore, a 
stretch of conserved hydrophobic residues between position 31-40 (Met31, Phe35, 
Leu38 and Leu40) of helix two have an effect on the nuclear and cytoplasmic 
distribution of NEP, as mutation of these residues to alanine resulted in NEP nuclear 
retention and also reduced virus growth (Huang et al., 2013). In another study, 
mutation of methionine at positions 14, 16 or 19 and leucine at position 21 which 
make up the first NES showed reduced growth of H1N1 virus in cell culture 
(Iwatsuki-Horimoto, Horimoto, Fujii, & Kawaoka, 2004).  
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The host protein AIMP2 which is a tumour suppressor was found to interact with 
NEP in the cytoplasm. AIMP2 binds at the NEP N-terminal to positively regulate virus 
replication by preventing degradation of the M1 protein required for vRNP export 
(Gao et al., 2015). Additionally, the cellular protein human nucleoporin 98 (hNup98) 
has been found to interact with NEP of H5N1 subtypes at the 22-53 region which 
causes NEP to co-localise in the nucleoli, but the significance of this interaction is 
unclear (Chen et al., 2010). Overall, these findings suggest that the high 
conservation of the N-terminal region could be attributable to these functions.  
The viral M1 protein binding site on helix three of the C-terminal region involves 
Trp78 and surrounding glutamate residues which are also highly conserved. This 
region is recognized by a nuclear localization signal (NLS) on the M1 protein (Akarsu 
et al., 2003; Shimizu, Takizawa, Watanabe, Nagata, & Kobayashi, 2011) which in 
turn is bound to vRNP’s to form the export complex. However, mutation of Trp78 was 
also reported to have no effect on vRNP export and NEP function (Robb et al., 
2009). Other highly conserved residues may have a role in maintaining the structure 
of the N-terminus, and forming recognition sites for other biomolecules.  
Regions of low conservation may indicate recognition sites by the host immune 
system. Previous conservation analysis of sequences for eleven influenza A proteins 
to identify conserved immunogenic peptides as vaccine targets predicted several 
potential T-cell epitopes, although sufficient sequence conservation for T-cell epitope 
predication was not identified for the NEP (Heiny et al., 2007). Upon antigen 
processing, the NEP induces a T-cell response, but unlike for HA and NA there are 
no reports of specific neutralising antibodies being produced. Therefore despite 
being conserved, if the protein is not sufficiently immunogenic or abundantly present, 
a NEP peptide based vaccine may induce very little, long term protective humoral 
immunity in vivo.  
Sequence variations may also be a result of subtype or species specific codon 
changes which have circulated and consequently lowered the alignment 
conservation score. Alanine at position 48 which displays intermediate conservation 
with a score of 0.791 enables efficient interaction with CRM1 and has been shown to 
reduce nuclear aggregation of NEP in a H1N1 strain (Gao et al., 2014). Significant 
differences between sequences could also lead to changes in biological functions 
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and enable the protein with additional features that could result in host adaptations. 
This is exemplified by a compensatory mutation found in the NEP sequence of a 
human H5N1 isolate at position 16 (M16I) which originated in birds and was found to 
enhance the activity of avian derived polymerases in human cultured cells (Mänz, 
Brunotte, Reuther, & Schwemmle, 2012). 
 
4.4.2 Structure and predicted binding site locations of the NEP 
 
To investigate binding hot spots as drug target sites in conserved regions, a full 
length NEP structure is required, which was not available from the PDB, hence 
protein structure prediction and molecular dynamics simulations were performed. 
Contrary to an experimental study focusing on NEP structure, the simulation 
trajectories and RMSD based cluster analyses reveal that the NEP is a stable 
structure and that the N-terminal does not display significant conformational 
flexibility; a feature which is proposed to assist in formation of the nuclear export 
complex (Lommer & Luo, 2002).  
Compared to the initial starting structure, helix one becomes slightly distorted 
throughout the 100 ns simulations with the end of the helix unravelling, whereas the 
structure of helix two mostly remains intact. The distances between the apex of the 
N-terminal and C-terminal helices also varies a little between simulations, 
presumably due to higher flexibility of the residues that form the loop connecting 
helix one and two, opening up a pocket at one end of the protein. Otherwise, no 
major structural changes occur that alter the predicted four helix bundle structure. 
Simple conventional MD simulations of nanosecond time scale provide an insight 
into structural dynamics of proteins, although, they do not provide complete 
conformational sampling, therefore more advanced methods would be required. 
Such methods developed for this purpose include 1) replica exchange MD, where 
independent parallel simulations (replicas) are run at different temperatures and are 
periodically exchanged depending on temperature and potential energy differences, 
2) accelerated MD, where a bias potential is added to raise the potential energy 
surface near the minima and accelerate simulation time and 3) metadynamics; a tool 
which broadly explores the free-energy landscape of biomolecules  (Bernardi, Melo, 
& Schulten, 2015; Gedeon, Thomas, & Madura, 2015).  
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The disorder prediction (DISOPRED3) result shows that the NEP structure is not 
intrinsically disordered, which supports the MD simulation results. Although, the low 
confidence score may be because of a low match between any potentially 
disordered regions of the NEP amino acid sequence against sequences of proteins 
that have missing regions of electron density in their PDB structures (Jones & 
Cozzetto, 2015). Despite cluster structures from each simulation being similar based 
on the protein backbone conformation, different binding hot spots were predicted for 
the three largest cluster structures by the FTMap server. This was most likely caused 
by different orientations of amino acid side chains such as those at positions 21-30, 
which permit different interactions with molecular probes. However, between the 
three structures, many binding hot spots were predicted in similar locations and 
close to the same residues. Most hot spots were located in conserved areas of the 
protein and several sites were predicted close together. Two hot spots were 
identified near the first nuclear export signal region (residues 11-23), either side of 
helix one on all three structures. The specific NEP-CRM1 binding location which has 
also been shown to be independent of the nuclear export signals (Huang et al., 
2013; Neumann et al., 2000), may involve N-terminal residues on the outer face of 
the protein which form these hot spots. One hot spot on all structures was identified 
in close spatial proximity to residues 74-82 of helix three, which forms the viral M1 
protein binding site.   
Several other NEP binding proteins have been discovered, such as ATP5E, HINT2, 
SMC3 and F1F0-ATPase; however, their binding site locations are unknown (Gao et 
al., 2015; Gorai et al., 2012). As interaction with these proteins may have indirect 
effects on influenza replication, it is possible that their binding locations may coincide 
with predicted hot spots identified in this work. Those hot spots which are the same 
across the three structures are presumably important interaction sites with other 
biomolecules, as they are unaffected by different conformation states. As common 
hot spots in the hydrophobic region between helix two and four were predicted for all 
three structures, and consisted of several highly conserved residues, this part of the 
protein was selected as the target site for screening. This region was also identified 
to interact with several different FTMap probes.   
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4.4.3 Virtual screening 
 
From the NCI library, compounds such as ZINC01717023 and ZINC01561925, 
which have comparable high binding affinities and similar docking poses predicted 
using both AutoDock Vina and AutoDock 4 could be the best candidate inhibitors. All 
of the top compounds from the combined rank list contain aromatic rings but their 
overall structures are very diverse. The predicted binding modes show that many of 
the top compounds bend around a cleft on the surface of the protein. Specific 
molecular interactions were analysed using the software LigPlot+, as shown in figure 
32. The compound ZINC0150994 specifically interacts with Arg42 on helix two and 
Ala102 on helix four via hydrogen bonding, as well as Leu106, Leu105, Val109, 
Gln101 and Lys39 through hydrophobic interactions.  
The top compound from the DrugBank library (Nandrolone phenylpropionate) is held 
in place between helices two and four through hydrophobic interactions only, with 
several surrounding residues of the target site. The DrugCard entry (DB00984) in the 
DrugBank database (Law et al., 2014; Wishart et al., 2006) states that this drug 
targets androgen receptors and can be used to treat haematological disorders, 
growth failure and Turners syndrome. Binding of larger compounds such as 
ZINC01561925 could partly block recognition of the second nuclear export signal on 
helix two, or accessibility of other binding proteins.  
The overall binding affinity distribution for molecules from the NCI library and 
DrugBank library are quite similar between AutoDock 4 and AutoDock Vina, as 
shown in the graphs in figures 28-31. The bulk of binding affinities could be 
represented by molecules/drugs which have a common scaffold that display the 
same molecular interactions and therefore bind with an affinity of ~-5.0 kcal/mol to 
the target site. However, the distribution amongst outliers is less comparable 
between the software for the NCI library, as 716 molecules were identified with a 
binding affinity between -7.0 kcal/mol and -9.0 kcal/mol with AutoDock Vina, 
compared to 176 with AutoDock 4. These molecules may have structural features 
more specific to the target site, although many of these could be false positive 
predictions. Also, for both libraries a higher number of molecules with scores 
between -3.0 kcal/mol and 0 kcal/mol screened with AutoDock 4 are outliers from the 
bulk of binding affinities compared with AutoDock Vina. 
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5 THE POLYMERASE BASIC PROTEIN 2 (PB2) 
5.1 INTRODUCTION 
 
This chapter describes the work published in Patel & Kukol, (2017). The polymerase 
basic protein 2 (PB2) is encoded by RNA segment one. It is one of the largest 
influenza proteins consisting of 759 amino acids and is a constituent subunit of the 
trimeric viral polymerase complex. During transcription of the viral genome, the PB2 
protein is mainly responsible for generating the cap structure for viral mRNA’s from 
the 5’ end of 7-methyl guanosine triphosphate (mGTP) capped host mRNA strand. 
The PB2 ‘cap snatching’ mechanism involves residues between positions 318-482 
which recognise methylated guanosine in order to bind the host cell RNA strand. The 
endonuclease subunit of the PA then cleaves the RNA, leaving a 10-13 nucleotide 
primer to initiate transcription by PB1 (Fodor, 2013). In complex, the N-terminal  
residues of the PB2 subunit are associated with the C-terminal subunit of PB1, which 
is a critical interaction to trigger acid polymerase (PA) endonuclease activity 
(Sugiyama et al., 2009). A detailed diagram of the PB2 subunit is presented in figure 
33. 
A structural study of the PB2 protein from a H5N1 avian virus had found that 
following translation, the C-terminal domain (residues 536-759) undergoes large 
conformational re-organisation between open and closed states. This flexibility 
enables the nuclear localization signal (NLS) peptide in the 686-759 region to bind 
with host importin-α, enabling PB2 entry into the nucleus of the target cell to catalyse 
further RNA transcription (Das, Aramini, Ma, Krug, & Arnold, 2010; Delaforge et al., 
2015). Other PB2 conformational changes occurring in connection with the cap-
snatching mechanism and the kind of RNA bound have also been described in the 
context of the full polymerase complex (Reich et al., 2014; Thierry et al., 2016).  
In addition to mutations in the HA and NA proteins, changes in the sequences of 
polymerase proteins are considered as major determinants of host range and 
adaptation (Mehle & Doudna, 2009; Neumann & Kawaoka, 2015). The characteristic 
PB2 host determining residue at position 627 (with lysine being prevalent in human 
strains, glutamate present in avian strains and serine in bat strains) is situated in a 
loop region, which along with the cap-binding domain, does not make extensive 
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contact with the PB1 and PA subunits (Kuzuhara et al., 2009; Pflug, Guilligay, Reich, 
& Cusack, 2014). The C-terminal 535-684 domain has also been shown to have 
RNA binding activity which is affected by the E627K mutation and is unrelated to the 
cap-snatching function (Kuzuhara et al., 2009).  
As well as localising in the nucleus, the PB2 subunit interacts with mitochondrial 
antiviral signalling protein (MAVS) (Graef et al., 2010); a feature unrelated to 
genome replication. PB2 proteins of seasonal human strains have been found to be 
present in the mitochondria, whilst PB2 proteins of avian strains (such as H5N1) 
were not. This difference in localization is caused by a single amino acid 
polymorphism in the mitochondrial targeting signal which has been mapped to the N-
terminal region at position nine (N9D). The significance of this finding is that non-
mitochondrial associated PB2 variants induce higher levels of IFN-β in vitro, 
suggesting that PB2 also plays an important role in determining virulence by altering 
the immune response (Graef et al., 2010).  
As the PB2 protein plays multiple essential roles in the virus life cycle, it is a valid 
target for antiviral drugs. Several crystal structures are available in the PDB for 
specific PB2 subunit domains in holo and apo forms which can aid with structure 
based drug discovery studies. Despite some of the PB2 surface area being 
inaccessible due to trimer assembly, inhibitors of the ‘cap snatching’ function to 
prevent capped host mRNA binding have been identified from cell based assays 
(figure 34) that have shown potent effects against several influenza strains in vitro 
(Boyd et al., 2015; Clark et al., 2014; Pautus et al., 2013). One of these compounds 
(VX-787, figure 34a) is currently undergoing clinical trials (Koszalka, Tilmanis, & 
Hurt, 2017). 
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Figure 33. PB2 subunit showing the C-terminal third and N-terminal two thirds with 
secondary structure elements of the sub-domains coloured and labelled. Adapted by 
permission from Macmillan Publishers Ltd: Nature (Pflug et al., 2014), copyright (2014). 
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5.2 METHODS 
 
5.2.1 PB2 sequence analysis 
 
The sequence analysis was performed according to general methods section 2.2. 
Briefly, full length PB2 sequences were chosen from all hosts, regions and subtypes 
until January 2016. Identical sequences and sequences containing non-standard 
residues were removed. The CD-HIT web server (Huang et al., 2010) was used to 
cluster sequences meeting a similarity threshold of 98.5%, as this gave an 
acceptable number of sequences for further analysis. Global pairwise sequence 
alignment between the H5N1 (A/Vietnam/1203/2004) and H17N10 (A/little yellow-
shouldered bat/Guatemala/060/2010) sequence was performed using the EMBOSS 
Needle tool version 6.6.0 (http://www.ebi.ac.uk/Tools/psa/emboss_needle/) with the 
default settings. For calculation of amino acid conservation see general methods 
section 2.3. The minimum score used for re-scaling was 0.789. 
 
5.2.2 Protein modelling 
 
The structure of a full length amino acid sequence of the PB2 polymerase isolated 
from a human host (A/Vietnam/1203/2004 (H5N1)) was predicted with the I-TASSER 
server (Yang & Zhang, 2015; Zhang, 2008). The I-TASSER model was aligned with 
the crystal structure of A/Vietnam/1203/2004 (PDB ID: 3L56) and the aligned 
coordinates were saved as a PDB file using PyMol. Experimentally known 
coordinates of residues 542-673 and 690-738 were copied from the crystal structure 
into the model. Missing atoms and side chains were inserted with Swiss-PDB Viewer 
version 4.1.0. 
Energy minimization was performed in solvent with 1000 steps of the steepest 
descent algorithm to remove atomic clashes and to optimise torsion angles of the 
PB2 model. The PDB file was converted to a Gromacs file and molecular topology 
file with the program pdb2gmx. The AMBER99SB – ILDN force field was selected as 
it demonstrated high accuracy in a systematic evaluation of eleven molecular 
dynamics force fields (Beauchamp et al., 2012) along with the TIP3P water model. 
The protein was solvated in water in a cubic box with periodic boundary conditions, 
and the charge of the chemical system was neutralised with 21 chloride ions and 
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additional NaCl at 100 mM concentration. The particle mesh ewald algorithm for 
calculating electrostatic interactions was used with a real space cut-off distance of 
1.0 nm and the cut-off for van der Waals interactions was 1.0 nm. The following 
commands were used: 
$ pdb2gmx -f PB2complete.pdb -o PB2complete.gro -p PB2complete.top -ter –ignh 
$ editconf -f PB2complete.gro -d 0.75 -o box.gro -bt cubic 
$ genbox -cp box.gro -cs spc216.gro -p PB2complete.top -o PB2solvated.gro 
$ grompp -f ions.mdp -p PB2complete.top -c PB2solvated.gro -o ions.tpr 
$ genion -s ions.tpr -neutral -conc 0.1 -p PB2complete.top -o ions.gro 
$ grompp -f em.mdp -p PB2complete.top -c ions.gro -o em.tpr 
$ mdrun -s em.tpr -c PB2after_em.gro 
$ editconf –f PB2after_em.gro –o PB2after_em.pdb 
 
5.2.3 Prediction of binding hot spots 
 
The PB2 model after energy minimisation was uploaded to the FTMap server 
(Brenke et al., 2009). See general methods section 2.5. 
 
5.2.4 Virtual screening - benchmarking  
 
Five previously identified compounds which have shown to inhibit influenza 
replication in vitro and are reported to bind the PB2 polymerase (Clark et al., 2014; 
Pautus et al., 2013) were used to benchmark virtual screening methods to find the 
best method of identifying true positives at the top of the rank list. The structures of 
the active compounds and their PDB codes are shown in figure 34. These 
compounds were downloaded from the PDB and converted to the PDBQT format 
with the script ‘prepare_ligand4.py’, which is included in the AutoDock Tools 
package. The following parameters were specified: add hydrogen atoms and build 
bonds between any non-bonded atoms, merge both non-polar hydrogens and lone 
pairs, and allow peptide-backbone-bonds to rotate. The three methods tested were: 
AutoDock Vina version 1.1.1 (Trott & Olson, 2010), AutoDock 4 (Morris & Huey, 
2009), and a consensus method using both (Kukol, 2011). 180 decoy molecules with 
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similar molecular weight from the NCI Plated 2007 library were selected for the 
benchmarking. The grid parameters for the benchmarking were set around the 
mGTP binding pocket and remained the same as those reported in the publication by 
Pautus et al., (2013). The top ten positions of all 185 compounds ranked according 
to their binding affinity were considered for identifying the known inhibitors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Chemical structures and PDB-IDs of five PB2 inhibitor compounds for 
benchmarking virtual screening methods.  
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5.2.5 Virtual screening against PB2 target site 
 
A region encompassing binding hot spot two was selected as the target site for 
virtual screening. The grid box dimensions for docking were set using AutoDock 
Tools as follows with a grid spacing of 0.375 Å: 
center_x = 58.942 
center_y = 70.112 
center_z = 63.114 
size_x = 22.5 
size_y = 20.25 
size_z = 20.25 
exhaustiveness = 12 
The same compound library used for screening against the NS1 protein was filtered 
using the software Open Babel version 2.3.1 (O’Boyle et al., 2011) to eliminate 
compounds with molecular weight over 500 g/mol and predicted partition co-efficient 
(logP) over five using the command: 
$ obabel output.mol2 --filter “MW<500 logP<5” –O filtered.mol2     
The remaining 46,926 chemical compounds in .mol2 format were split into individual 
ligand files and saved in PDBQT format using the AutoDock screening preparation 
tool Raccoon.  
Post screening, the library was converted to SDF format and passed through the 
Pan Assay Interference Compounds (PAINS) filter with the online FAF-Drugs3 (Free 
ADME-Tox Filtering Tool) program (Baell & Holloway, 2010; Lagorce et al., 2015) to 
identify and remove compounds from the rank list that appear as frequent hitters in 
screening experiments. A total of 42,348 compounds remained. The DrugBank-
approved library containing 1738 drugs (Law et al., 2014) was downloaded from the 
ZINC database and also screened against the PB2 target site in order to find any 
approved drugs that may also target the PB2.  
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5.3 RESULTS 
 
5.3.1 PB2 amino acid conservation 
 
12,459 PB2 sequences were obtained from the NCBI influenza virus resource 
database. This included 31% from human, 16% from swine and 50% from avian 
hosts. 702 sequences remained after removing redundant sequences at 98.5% 
identity. The conservation scores calculated from the multiple sequence alignment of 
the non-redundant sequences shows that there is a high level of amino acid 
conservation throughout the entire protein sequence. The scores ranged from 0.789 
(lowest) at position 147 to 1.0 (highest) and the majority of amino acids had a score 
between 0.95 and 1.0 (table 19, appendix 9.3). Overall, the key functional regions of 
the protein were found to be well conserved. 42 amino acids were found to be 100% 
conserved in the dataset. Low (scores below 0.850) or moderate conservation was 
identified mainly at single amino acid positions such as 64, 107, 147, 271, 292, 453, 
483, 559, 588, 590, 591, 613, 661 and position 676 which were all located on the 
exterior surface of the protein. An intermediate level of conservation for the host 
specific residue at position 627 was reflected in the alignment with a conservation 
score of 0.885. For display purposes the conservation scores were re-scaled and 
mapped on to the PB2 structure (figure 35). 
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Figure 35. PB2 amino acid conservation mapped onto the H5N1 influenza A PB2 protein 
structure shown in (a) cartoon representation and (b) spacefill representation. Figure 
adapted from Patel & Kukol, (2017).  
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5.3.2 Protein modelling 
 
The I-TASSER model of the human H5N1 sequence had a template modelling (TM) 
score of 0.92, and was largely built on the PDB template 4WSB chain C, which is 
from a H17N10 subtype of bat influenza A. Residues 483-490 and 742-759 which 
were not covered by any template were modelled ab-initio. The H5N1 PB2 fragment 
(3L56) is structurally very similar to that of H17N10 with a backbone RMSD of 1.05 
Å. The final model was refined by energy minimisation. The overall percentage 
identity between the two full length sequences is 68% and the overall similarity is 
83% calculated using the EBLOSUM62 matrix. The pairwise alignment of the two 
sequences covering some of the amino acid residues surrounding the target site 
selected for virtual screening is shown in figure 36. Many of the residues in the target 
site are located far apart in the amino acid sequence. Residues with an exposed 
surface area above 2.5 Å2 were considered as exterior residues.  
 
Figure 36. PB2 H5N1 (A/Vietnam/1203/2004) and H17N10 (A/little yellow-shouldered 
bat/Guatemala/060/2010) pairwise sequence alignment of the region 101-150 and 501-550 
covering the target site for virtual screening. A vertical line indicates identical residues, a 
colon indicates strong similarity and a period indicates weak similarity. 
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5.3.3 Computational solvent mapping 
 
Fifteen ligand binding hot spots were predicted using FTMap in several domains, 
most of which were located in highly conserved areas of the protein. The top ten 
binding hot spots are annotated in figure 37. The most surface accessible spots are 
site three, four, five, six, seven, eight, nine, fourteen and fifteen. Hot spots two, 
eleven, twelve and ten appear to be partially buried when viewing the structure in 
spacefill representation, with sites one and thirteen being the least exposed to the 
outer surface on the protein core. The highest number of different probes were found 
to bind at site one. Site seven, fourteen and fifteen were clustered closely together in 
the mGTP capped RNA binding region, whereas site six was the only site located 
within the N-terminal third. Site three is close (within ~6.0 Å) to the intermediately 
conserved residue Val613. It was decided to consider the conserved region 
encompassing hot spot two as the target site for virtual screening. 
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Figure 37. Locations of the top ten binding hot spots (green spheres) identified by the 
FTMap algorithm shown together with the degree of PB2 sequence conservation on (a) the 
H5N1 PB2 structure (Patel & Kukol, (2017)) and (b) the H5N1 PB2 subunit structurally 
aligned with the H17N10 polymerase complex. The numbers indicate the rank assigned by 
the FTMap algorithm. 
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5.3.4 Virtual screening - benchmarking 
 
A virtual screening benchmark was performed against the mGTP capped RNA 
binding site. The ability of the docking software to identify five known inhibitors 
among the top ten predictions out of 180 compounds with similar molecular weight 
was tested. The results showed that AutoDock Vina alone and a combination with 
AutoDock 4 were the best method to retrieve active compounds within the top 
positions of the rank list as both methods were able to identify one inhibitor (table 
13). The binding affinities using AutoDock Vina ranged from -7.4 kcal/mol to -4.5 
kcal/mol and from -7.4 kcal/mol to -2.9 kcal/mol with AutoDock 4. For simplicity, the 
single AutoDock Vina software was used for the PB2 target site screening. 
 
Table 13. Results from benchmarking three docking software for virtual screening. 
Software Number of true ligands 
found within top 10 
Binding affinity of ligand 
(kcal/mol) 
AutoDock Vina  1 -7.4 
AutoDock 4 0  
AutoDock Vina + 
AutoDock 4  
1 -7.4+ -6.0 
 
 
5.3.5 Virtual screening - PB2 target site 
 
The binding affinities of 46,926 compounds screened from the NCI library ranged 
from -10.3 kcal/mol to +13.7 kcal/mol using AutoDock Vina (figure 39). A large 
proportion of compounds were predicted to bind between the range of -5.0 kcal/mol 
and -7.0 kcal/mol. Fourteen ligands had binding energies above zero kcal/mol, (not 
shown on the energy distribution graph in figure 39) and several molecules at the top 
of the rank list had similar chemical structures. All compounds identified as PAINS 
were removed from the rank list to help selection of top hit compounds. Some of the 
key amino acid residues found to interact with the top ten compounds via hydrogen 
bonding and hydrophobic interactions include: Gln138, Gly222, Ile529, Ile539, 
Asn540, Gly541, Tyr531 and Thr530; all of which are highly conserved. The 
predicted binding conformations show that some of these compounds bind partially 
inside a deep pocket formed by these residues (figure 38). 
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The DrugBank-approved library containing 1738 small molecule drugs was also 
screened against the same target site. The binding scores ranged from -10.0 
kcal/mol to +53.8 kcal/mol with the largest proportion of drugs predicted to bind 
between the range of -5.0 kcal/mol and -7.0 kcal/mol. 32 drugs had a positive 
binding score above zero kcal/mol (not shown on the energy distribution graph in 
figure 40). None of the approved drugs had a significantly stronger predicted binding 
affinity than the top ranked compound of the NCI library; however, the highest 
ranked drug paliperidone (ZINC04214700) had the same binding affinity (-10.0 
kcal/mol) as three compounds of the NCI library ranked within the top ten positions. 
The chemical properties of top hit compounds from both libraries are shown in table 
14. 
 
 
Figure 38. Chemical structure and docking models of top hit compounds targeting the PB2 
protein: ZINC05543024 and paliperidone identified by virtual screening using AutoDock 
Vina. Interacting PB2 residues are labelled. Figure adapted from Patel & Kukol, (2017).  
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Figure 39. Binding energy distribution graph of compounds screened from the NCI library 
using AutoDock Vina. (Negative binding scores shown only). 
 
Figure 40. Binding energy distribution graph of compounds screened from the DrugBank-
approved library using AutoDock Vina. (Negative scores shown only). 
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Table 14. Chemical properties and binding affinity (ΔG) of predicted top hit compounds 
identified from virtual screening of the NCI and DrugBank library obtained from the ZINC 
database. Properties include molecular mass (Mol M), predicted partition coefficient (xLogP), 
no. of hydrogen bond donors and acceptors and total polar surface area (tPSA) at pH7. 
Compound  
(ZINC ID) 
ΔG 
(kcal/mol) 
Mol M 
(g/mol) 
xLogP H Don H Acc tPSA 
(Å2) 
NCI library       
ZINC01617371  -10.3 390.42 2.69 1 7 115 
ZINC05543024  -10.2 291.31 2.46 2 3 74 
ZINC01612458  -10.1 328.76 4.26 2 6 80 
ZINC03954617  -10.1 288.31 1.31 2 6 83 
ZINC01040450  -10.0 354.32 3.46 2 9 103 
ZINC08651894  -10.0 446.93 3.18 2 9 131 
ZINC13212434  -10.0 359.84 2.51 4 6 82 
ZINC01624487  -9.9 369.83 3.80 1 5 82 
ZINC01612446  -9.8 404.73 3.66 2 12 171 
ZINC01614027  -9.8 318.40 4.27 1 3 41 
DrugBank library       
Paliperidone -10.0 427.50 1.97 2 7 86 
Paliperidone  -9.9 427.50 1.97 2 7 85 
Risperidone -9.4 411.50 2.96 1 6 65 
Sulfasalazine  -9.4 397.39 4.08 2 9 147 
Folic acid  -9.4 439.39 -2.37 5 13 219 
Nebivolol  -9.0 406.45 3.10 4 5 75 
Alimta  -8.9 425.40 -1.53 5 11 197 
Iloperidone  -8.8 427.50 3.95 1 6 66 
Rivaroxaban -8.8 435.89 2.53 1 8 88 
Dantrolene sodium  -8.7 314.26 1.75 1 9 121 
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5.4 DISCUSSION 
 
5.4.1 PB2 conservation 
 
Regions of structural and functional importance that displayed high conservation 
include the N-terminal residues 1-37 which form three short α-helices comprising the 
PB1 binding interface required for effective polymerase activity (Sugiyama et al., 
2009). The mGTP cap binding region is also well conserved, albeit with moderately 
conserved residues at position 339, 340, 453 and 456. Substitution of Lys339 to 
Thr339 in the cap binding domain of certain subtypes has been found to prevent 
binding of the phosphate group of mGTP capped mRNA, reducing RNA synthesis, 
and thereby regulating PB2 activity (Liu et al., 2013). Within this domain, Val414, 
Arg415 and Gly416 are highly conserved and are required for PB2-acetyl-CoA 
interaction to maintain transcription activity (Hatakeyama et al., 2014). The 424-loop 
region is suggested to have an allosteric role in regulating PB1 activity, whilst other 
conserved residues are expected to contribute to the domains structurally distinct 
fold which allows formation of intermolecular contacts specific for mGTP cap binding 
activity (Guilligay et al., 2008). 
The 1-269 and 580-683 segments which are reported to be capable of binding the 
nucleoprotein (NP) (Poole, Elton, Medcalf, & Digard, 2004), also consist of long 
stretches of conserved residues such as Ser592-Thr612. A total of 42 amino acids 
were found to be 100% conserved and could therefore be the most resistant to 
change due to evolutionary adaption of the virus. This includes Leu744 located on a 
surface exposed loop region, and Gly693, which are suggested to be key residues in 
the NLS region due to their high conservation, enabling PB2 nuclear entry from the 
cytoplasm via binding importin-α. Other highly conserved regions with unassigned 
functions identified in this work may be of interest with regards to further 
investigations of structure and function of the PB2 protein. 
Amino acid residues displaying low or moderate conservation were mostly located 
on the exterior surface of the protein (figure 35), which is consistent with the finding 
that surface residues evolve faster than those in the protein core (Warren et al., 
2013). The residues neighbouring less conserved positions were generally found to 
be highly conserved, as well as 16% of residues located in the interior of the protein. 
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Their restricted variability is presumably essential for maintaining the protein 
structure, in particular the subdomains. 
Due to the majority of sequences being from avian hosts, glutamic acid was the 
prevalent residue at position 627 based on the consensus sequence. The E627K 
mutation is well known for determining virulence by increasing polymerase activity 
and replication in mammals. This prime example of host adaptation is thought to be 
due to glutamic acid being able to bind the avian version of the host cell factor 
ANP32A; whereas substitution to lysine allows the polymerase to bind to the 
mammalian version of this host factor (Long et al., 2016; Moncorgé, Mura, & Barclay, 
2010). However, some avian viruses carrying the E627 variant can efficiently 
replicate in mammalian cells due to compensatory mutations found in the PB1 
protein of H5N1 strains (Xu et al., 2012). A mutation study of the 627 domain has 
also identified specific conserved residues to be essential for general PB2 activity 
(Arg597, Pro620, Phe621, Arg646 and Arg650), as well as non-essential residues 
such as Pro625, Pro626 and Gln628, which are also highly conserved (Kirui, Bucci, 
Poole, & Mehle, 2014). Furthermore, the positive charge of the highly conserved 
Arg630 (in the presence of nucleoprotein (NP) R150), or Lys627 promotes PB2-NP 
interaction, which is essential for the ribonucleoprotein complex to provide structural 
maintenance and regulate viral transcription (Ng et al., 2012). Adaptive mutations to 
Ala271, Arg591, and Ser590 have also been found to enhance polymerase activity 
and virus replication in mammals (Bussey, Bousse, Desmet, Kim, & Takimoto, 2010; 
Mehle & Doudna, 2009; Yamada et al., 2010). The remaining non-conserved 
positions may also be associated with determining host range, virulence, PB2 
cellular localization, or with no particular function.  
The protein sequence dataset analysed contains two sequences isolated from bats 
(including the H17N10 strain for which a crystal structure has been resolved, PDB 
ID: 4WSB), which are noticeably different to the consensus sequence. Influenza 
protein sequences isolated from bats have shown less similarity overall to 
sequences from other hosts (Tong et al., 2013). Despite these differences, the 
H17N10 sequence for PB2 remains evolutionary close to human and avian strains 
(Pflug et al., 2014) and is therefore unlikely to result in major structural differences. 
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5.4.2 Predicted binding hot spots 
 
Computational solvent mapping identified fifteen potential binding hot spots which 
represent favourable binding regions with small organic molecules. Most of these 
were located within residues towards the C-terminal part of the polypeptide chain. 
Based on previous structural information reported and the flexibility of viral 
polymerase subunits in general (Reich et al., 2014; Thierry et al., 2016), the surface 
accessibility of some of these binding hot spots may change upon trimer formation or 
subdomain rotation. Structural alignment of the H5N1 PB2 structure with 4WSB 
chain C (figure 37b), suggests that the accessibility of these sites would be 
unaffected as they are not directly blocked by PA/PB1 in complex. Whereas, 
alternative configurations of the heterotrimer (reviewed by (Pflug, Lukarska, Resa-
Infante, Reich, & Cusack, 2017)) have shown that depending on the RNA promoter 
bound, the PB2 cap-binding, 627 and NLS domains may exist in several states in 
influenza B and C polymerases. This suggests that accessibility of all hot spots 
(except for six, nine, ten and thirteen which are not located within these domains) 
could change.  
 
The highest number of different probes (ten) were found to bind at hot spot one, 
which indicates that this area has good binding potential with a variety of functional 
groups. Spots seven, fourteen and fifteen are clustered closely together forming the 
conserved mGTP cap binding site, and considering the functional importance of this 
region, the low ranking assigned is probably due to the affinity for the highly charged 
RNA molecules, which are not well represented by the library of organic solvents 
used in the docking with the FTmap algorithm. However, these spots are near the 
binding site for the PB2 inhibitors identified by Clark et al., (2014) (methylguanine 
derivatives) and Pautus et al., (2013) and consist of residues involved in hydrogen 
bonding. 
 
Amino acids surrounding spots one, seven, fourteen and fifteen are not involved in 
heterotrimer formation and are located at positions set apart from the PA/PB1 
subunit interactions. Spot six is the only one located within the N-terminal third and 
could be implicated in trimer association. The conserved region encompassing hot 
spot two was selected as the target site for docking, as the residues closely 
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surrounding this hot spot display high conservation so are less likely to mutate. Also, 
this hot spot is second ranked, as several different probe types were predicted to 
bind there, suggesting it is an important site of the protein (Brenke et al., 2009), and 
this site has not previously been targeted by virtual screening experiments. 
Furthermore, there are currently no identified inhibitors which target this hot spot. In 
relation to PB2 structure and function, the residues surrounding this spot may be 
associated with rotation of the C-terminal domain, or contribute towards interactions 
with PB1. 
 
5.4.3 Virtual screening 
 
Some of the key amino acid residues found to interact with the top compounds via 
hydrogen bonding and hydrophobic interactions using the LigPlot+ software include: 
Gln138, Gly222, Ile529, Ile539, Asn540, Gly541, Tyr531 and Thr530; all of which are 
highly conserved. The predicted binding conformations show that some of these 
compounds bind partially inside a deep pocket formed by these residues between 
two loop regions (figure 38). Compound 1 (ZINC01617371) forms hydrophobic 
contacts with eighteen residues and a single hydrogen bond with Ile529 at a distance 
of 3.12 Å. The compound bends around the 531-541 loop region causing the phenyl 
ring and nitrile group to be entirely buried within the protein; the methyl group at the 
other end is surface exposed. Also, three aromatic groups of compound 4 
(ZINC03954617) form hydrogen bonds with Gly222, Gln241 and Ile529, and are 
surrounded by eleven residues forming hydrophobic contacts. The top ten 
compounds share the common scaffold of an aromatic group at one or both ends, 
occupying the binding pocket in a similar orientation as compound 2 (ZINC05543024 
(figure 38)), supported by van der Waals and electrostatic interactions between 
atoms. The compounds may inhibit virus replication by interfering with host protein 
interactions, with trimer assembly by restricting or inducing conformation changes, or 
with the synthesis of RNA (Thierry et al., 2016); the ligands predicted in this study 
could serve as tools to investigate such functions, or be used as a starting point to 
develop clinically active anti-influenza drugs. 
The drug paliperidone is approved by the Food and Drug Administration (FDA) for 
the treatment of schizophrenia and related disorders. It binds to the dopamine and 
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serotonin receptors, although the exact mechanism of action is not known (reviewed 
in Corena-McLeod, (2015)). Paliperidone is a large compound occupying most of the 
binding pocket; the nitrogen atom of the central pyridine ring is able to form a 
hydrogen bond with the oxygen atom of Glu241, and the drug-protein complex is 
maintained via hydrophobic contacts with sixteen surrounding residues of the target 
site. The results of this study may be useful for repurposing this drug or derivatives 
as a treatment for influenza A infection.  
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6 EVALUATION OF A NOVEL VIRTUAL SCREENING STRATEGY 
USING RECEPTOR DECOY BINDING SITES  
 
6.1 INTRODUCTION 
 
This chapter describes the development and evaluation of a novel yet 
straightforward receptor-decoy strategy that aimed to improve molecular docking 
predictions (Patel & Kukol, 2016a). Several tools for molecular docking and virtual 
screening are available (Plewczynski, Łaźniewski, Augustyniak, & Ginalski, 2011) 
and have been evaluated on various protein-ligand complexes (Li, Li, Cheng, Liu, & 
Wang, 2010; Tuccinardi, Poli, Romboli, Giordano, & Martinelli, 2014). Although 
docking provides an efficient and cost effective way to assess interactions between 
molecules such as proteins and ligands on a large-scale, the accuracy, as defined by 
the ability to predict strong binding ligands, is limited. This is largely due to the 
limitation of scoring functions used in the software to calculate binding energies, and 
therefore their ability to identify true positives from a database composed of known 
ligands and decoys (molecules with physical properties similar to known ligands but 
dissimilar topology) that is typically used in evaluations of virtual screening (Huang, 
Shoichet, & Irwin, 2006; Kitchen et al., 2004). The accuracy of the screening method 
can be assessed quantitatively through calculation of the robust metric known as 
Receiver Operator Characteristic Enrichment (ROCE) (Nicholls, 2008). An ROCE 
factor is obtained as the true positive rate divided by the false positive rate, therefore 
ROCE factors much larger than 1.0 are desirable to establish that the docking 
algorithm can distinguish active compounds from decoys.  
 
Methods to increase the accuracy of virtual screening have previously been 
suggested, for example, considering receptor flexibility to reduce the numbers of 
false positive molecules (Awuni & Mu, 2015), consensus docking to predict correct 
binding pose (Houston & Walkinshaw, 2013), and a consensus virtual screening 
method that combined the rank lists of ligands from up to three different algorithms 
(Kukol, 2011). However, these improved methods can still result in a low number of 
correct predictions for some receptors.  
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6.1.1 Aims and objectives 
 
This work aimed to improve the accuracy of molecular docking predictions, thus 
supporting the discovery of influenza A virus replication inhibitors. This was 
attempted by removing possible false positive compounds, which involves 
performing virtual screening against a non-binding (decoy) site on the same receptor 
protein target. A method to re-rank the screening results was developed, enabling a 
comparison of ROCE factors before and after the application of receptor-decoy 
screening in order to evaluate the novel strategy.  
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6.2 MATERIALS AND METHODS 
 
6.2.1 Materials 
 
Ligand and decoy sets for fifteen target proteins were downloaded from the 
Database of Useful Decoys (http://dud.docking.org) (Huang et al., 2006). The 
complexes were selected from several different protein categories in the database 
such as hormone receptors, kinases, proteases and other enzymes to represent a 
wide range of targets, including ten targets which had previously been used to 
evaluate common docking algorithms (Kukol, 2011). Ligand and decoy sets were 
converted from the .mol2 format to the PDBQT format using the screening 
preparation software Raccoon. The FTMap server (Brenke et al., 2009) was used to 
define the decoy site for docking. Virtual screening for all fifteen targets was 
performed using AutoDock Vina version 1.1.1 with the default parameters on the 
University of Hertfordshire high performance computer cluster.  
 
6.2.2 Docking against the binding site and decoy site 
 
For each target, a text file with a list of decoys and a list of ligands was generated. 
The search space for docking was defined via a grid box manually specified with 
AutoDock Tools (Morris & Huey, 2009) around the binding or decoy site. A grid 
spacing of 0.375 Å was used to determine the box dimensions which remained the 
same for the binding and decoy site. The decoy site was chosen based on the 
following criteria: 1) contains no binding hot spot predicted by FTMap, 2) it appears 
structurally different to the actual binding site and 3) it does not form an obvious 
binding cavity, but is at a flat region on the exterior surface of the protein.  
 
6.2.3 Generating adjusted rank lists  
 
A script was used to generate adjusted rank lists from the binding site list by 
considering molecules that were in the top 10%, 15%, 20%, 30% and 50% of the 
decoy site list, and adjusting the rank of the binding site list based on the following 
formula: 
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𝑁𝑒𝑤 𝑟𝑎𝑛𝑘 = (𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝑠𝑖𝑡𝑒 𝑟𝑎𝑛𝑘 − 𝐷𝑒𝑐𝑜𝑦 𝑠𝑖𝑡𝑒 𝑟𝑎𝑛𝑘) +  𝑇𝑜𝑡𝑎𝑙 𝑛𝑜. 𝑜𝑓 𝑙𝑖𝑔𝑎𝑛𝑑𝑠 𝑖𝑛 𝑙𝑖𝑠𝑡 
As a result, molecules that received a high rank in the screening against the decoy 
site were assigned a much lower rank in the screening results against the binding 
site. 
 
The fraction of decoy-site docking results was varied in order to find a cut-off where 
maximum enrichment is achieved. With the example of the progesterone receptor 
(PR), the following command was used taking into account the top 10% of the 
decoy-site rank list with a weight of 1.0: 
$ perl RankAdjustDecoySite.pl pr_bindingsitelist.txt 
pr_decoysitelist.txt 10 1.0 > PR_decoyAdjust_10.txt 
The weight was always left at 1.0. 
 
 
6.2.4 Calculation of Receiver Operator Characteristic Enrichment (ROCE) 
 
The numbers of active ligands in the database were then used to calculate the 
ROCE factors at 1% and 2% of the number of molecules in each of the adjusted rank 
lists using a script. With the example of the receptor PR, the following command was 
used: 
$ perl CountLigands.pl PR_ligandsList.txt PR_decoyAdjust_10.txt 
(top) 
 
The ROCE was calculated as the fraction of true positives divided by the fraction of 
false positives at x% of the ligand/decoy database according to the equation: 
𝑅𝑂𝐶𝐸𝑥% =
𝑓𝑎𝑐𝑡𝑖𝑣𝑒𝑠
1 −
(𝑁𝑑𝑒𝑐𝑜𝑦𝑠 − 𝑁𝑖𝑛𝑎𝑐𝑡𝑖𝑣𝑒𝑠)
𝑁𝑑𝑒𝑐𝑜𝑦𝑠
 
 
Where factives = (number of actives at x%) / (number of all actives), Ndecoys = the total 
number of inactive decoys, Ninactives = the number of decoys chosen at x% of the 
ligand/decoy database. 
120 
 
 
6.2.5 Binding site and decoy site analysis 
 
Binding site and decoy sites were analysed post-docking with the KVFinder Cavity 
Detection PyMol Plugin (Oliveira et al., 2014) to provide a quantitative description of 
the two sites. The software enables comparison and characterisation of protein 
binding sites by the number, area and volume of cavities in a specified search space. 
The default parameters were used for all fifteen targets, which included a probe in 
size of 1.4 Å, probe out size of 4.0 Å and a step size of 0.6 Å. The minimum cavity 
volume was set at 5.0 Å. The binding site search space was set around the position 
of the actual ligand molecule obtained from the Protein Data Bank (as shown in 
figure 41), and the decoy site search space was set using a docked molecule from 
the decoy site screening. 
 
 
Figure 41. Screenshot of the KVFinder cavity detection software used to analyse the binding 
site for the protein Pparg. The box dimensions were set around the position of the actual 
ligand.  
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6.3 RESULTS  
 
6.3.1 ROCE at different fractions of the adjusted binding site rank list 
 
In this study, the level of Receiver Operator Characteristic Enrichment (ROCE) was 
determined at fractions of 1% and 2% of the dataset of ligand/decoy molecules. 
Performing the docking against a decoy site on the same receptor, as shown in 
figure 42, lead to a ranking of molecules different from the ranking for the true 
binding site. The predicted binding energies among top molecules for the decoy site 
were less negative than for binding sites, indicating a lower degree of binding to the 
decoy site. The ranking for the true binding site was adjusted by considering a varied 
fraction of the rank list produced from the decoy site from 0% (no correction) to 50% 
(table 15 and 16). Overall, the majority of targets did not show any improvement in 
enrichment at the top 1% or 2% of the list after applying the receptor decoy method.  
At 1% of the database, five targets (Comt, Ache, CDK2, HIVrt and Pparg) show 
improved ROCE factors compared to those obtained in the previous study (Kukol, 
2011 (see footnotes in table 15 and 16)), when considering at least the top 15% of 
the decoy site list. Beyond 15% the enrichment for most targets either remained 
constant or dropped to a lower value. 
 
 
 
 
 
 
 
 
 
 
 
Figure 42. (a) Ache receptor with the true binding site shown in red and decoy site in blue. 
(b) detailed view of the Ache binding site. (c) Detailed view of the Ache decoy site. Figure 
reproduced from Patel & Kukol (2016a). 
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Table 15. ROCE at 1% of the binding site list considering top x% of the decoy site list. 
Numbers in bold indicate improvement over the unadjusted virtual screening. 
 Top % of decoy list 
Receptor 0 10 15 20 30 50 
Comt 33.41 39.0 39.0 39.0 39.0 39.0 
AchE 1.01 0.96 3.03 3.03 1.97 3.03 
CDK2 14.31 23.6 29.7 23.6 29.7 14.3 
HIVrt 9.41 13.1 13.1 9.0 13.1 18.0 
Pparg 58.81 99.0 84.0 84.0 84.0 84.0 
FGFR1 0.0 0.0 0.9 0.9 0.9 0.9 
InhA 14.6 5.3 5.3 5.3 2.5 0.0 
PR 0.0 0.0  0.0 0.0 0.0 4.0 
RXRa 212.4 212.4 212.4 88.5 47.2 88.5 
VEGFr2 10.2 2.9 2.9 2.9 1.4 1.4 
MR 178.3 178.3 71.3 71.3 71.3 7.1 
Hsp90 0.0  0.0 0.0 0.0 0.0 0.0 
ampC 0.0 0.0 0.0 0.0 0.0 0.0 
trypsin 5.0 5.0 5.0 5.0 5.0 5.0 
Parp 7.1 7.1 7.1 7.1 7.1 11.9 
1Results taken from (Kukol, 2011) 
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Table 16. ROCE at 2% of the binding site list considering top x% of the decoy site list. 
Numbers in bold indicate improvement over the unadjusted virtual screening. 
 Top % of decoy list 
Receptor 0 10 15 20 30 50 
Comt 10.41 11.2 11.2 11.2 11.2 11.2 
AchE 1.51 2.0 2.0 1.5 2.0 1.5 
CDK2 13.31 15.7 15.7 15.7 11.9 5.8  
HIVrt 8.81 9.0 9.0 7.2 7.2 11.0 
Pparg 35.81 58.0 54.0 58.0 50.0 44.0 
FGFR1 0.6 0.4 0.4 0.4 0.4 0.4 
InhA 12.4 3.1 3.1 2.5 1.2 0.0 
PR 0.0 0.0 0.0 0.0 1.9 4.0 
RXRa 70.8 97.4 70.8 40.5 17.7 23.6 
VEGFr2 5.3 1.4 2.1 2.1 2.9 1.4 
MR 62.4 42.8 29.7 20.4 20.4 3.6 
Hsp90 0.0 0.0 0.0 0.0 0.0 4.5 
ampC 0.0 0.0 0.0 0.0 0.0 0.0 
trypsin 5.0 5.0 5.0 5.0 5.0 5.0 
Parp 5.1 3.2 7.1 7.1 7.1 9.4 
1Results taken from (Kukol, 2011) 
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The largest improvement in enrichment was achieved with the targets CDK2 and 
Pparg. Figure 43 shows that the ROC curve with decoy site adjustment is either 
similar, or even below the unadjusted curve for the target CDK2. However, it is the 
early enrichment that is important when utilising virtual screening results for 
experimental testing (inset to figure 43). For the targets PR and Hsp90, the ROCE at 
1% and 2% remained at zero until considering at least 30% of molecules in the 
decoy list.  
 
 
Figure 43. Receiver Operator Characteristic (ROC) curve for the target CDK2 showing 
improved early enrichment with decoy site adjustment of 15% compared to no adjustment. 
The inset shows the early enrichment up to 5% of ligand/decoy molecules. 
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6.3.2 Binding site and decoy site analysis 
 
Cavity analyses of the binding site and decoy site (table 17) using the software 
KVFinder  (Oliveira et al., 2014) shows that the total number, volume and area of the 
cavities found in the decoy site were smaller in comparison to the binding site for all 
targets, except HIVrt and trypsin. This confirms that the shapes of the two sites are 
very different; although this does not prevent false positive molecules binding with 
high affinity.    
 
Table 17. Analysis of binding and decoy sites for all receptors based on the number, volume 
and area of cavities in the search space using KVFinder. 
 Binding site Cavities Decoy site cavities 
Receptor Number  Total 
Volume (Å3 ) 
Total 
Area (Å2 ) 
Number  Total Volume 
(Å3 )  
Total Area 
(Å2 ) 
Comt 1 29.8 45.7 1 12.3 20.3 
AchE 3 249.3 333.8 2 85.5 124.9 
CDK2 4 134.0 178.3 1 10.6 15.8 
HIVrt 5 92.1 138.7 1 241.3 240.1 
Pparg 2 394.4 414.8 1 8.6 14.4 
FGFR1 2 49.0 70.2 1 21.0 30.6 
InhA 2 1119.7 834.8 1 6.0 10.1 
PR 2 21.4 35.0 1 18.1 28.4 
RXRa 1 57.5 72.0 1 21.0 30.2 
Vegfr2 5 129.3 193.0 4 117.4 168.0 
MR 2 54.4 78.1 1 23.5 35.6 
Hsp90 4 166.8 233.7 2 30.0 46.1 
ampC 3 100.8 121.3 1 5.8 9.7 
trypsin 1 9.7 14.8 3 79.9 121.8 
Parp 1 538.3 482.4 1 9.9 16.6 
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6.4 DISCUSSION 
 
High predicted binding affinities between a ligand and a receptor may not always 
correspond with the best binding molecules for the target site investigated 
(Plewczynski et al., 2011; Wang, Lu, Fang, & Wang, 2004). In virtual screening, this 
is reflected by low enrichment factors, which indicate that many of the highest ranked 
molecules may be false positive predictions (Nicholls, 2008). The rationale behind 
the receptor decoy strategy was that the number of false positive binders could be 
reduced by determining molecules, which have a tendency to bind non-specifically to 
molecular surfaces. As a result, a higher number of active ligands would remain after 
processing the rank list for the true binding site with the rank list for the decoy site. 
However, the results show that this approach is unlikely to help in the identification 
and selection of molecules for experimental testing as a higher number of true 
positives were recalled for only five targets.  
 
The extent of enrichment achieved for the top 1% and 2% differed for all targets due 
to properties that determine the binding interactions between amino acid residues of 
the target and the ligand-decoy dataset used for docking. The optimum cut-off for 
maximum enrichment at the top 1% of a binding site list was obtained when 
considering 15% of the decoy list (table 15), and 10% for the top 2% of the binding 
site list (table 16). This shows that the ranking of molecules with regards to binding 
to the decoy sites is meaningless for lower ranks. For those targets where the ROCE 
factor remained at zero until considering at least 30% of the decoy list, indicates that 
true and false ligands cannot be distinguished by the AutoDock Vina docking 
algorithm. 
The results show a considerable variation between the fifteen targets investigated 
confirming the general consensus that virtual screening accuracy is highly 
dependent on the target. The targets Inha, MR and VEGFr2 show a significant 
decrease in ROCE, indicating this strategy makes the retrieval of active ligands in 
the top ranks worse for these targets. The actual binding site for VEGFr2 appears to 
be non-specific, open and flat, therefore binds molecules which also bind easily to 
the decoy site, resulting in a high proportion of active molecules at the top of the 
decoy list. However, the Inha binding site is a small, deep pocket with a total cavity 
area of 838.4 Å2 which appears not to be easily surface accessible, so it is expected 
127 
 
 
that this receptor only binds ligands which are complementary in shape. Although, 
this was not seen as a higher number of active ligands were found in the top 1% of 
the decoy site list compared to the binding site list. Thus, when the re-ranking 
formula to generate the adjusted list is applied, the binding site list is re-ordered such 
that the active ligands do not appear in the top positions. This highlights the 
shortcoming that if applying this strategy to a virtual screening experiment where 
active molecules are not known, it cannot be guaranteed that any improved 
prediction accuracy will result.  
 
6.4.1 Conclusion 
 
The novel development and evaluation of docking with a decoy binding site shows 
that improved prediction of active ligands could not be achieved in general. It should 
be noted that the ligand/decoy dataset used for this evaluation is especially 
challenging as decoys with physico-chemical properties similar to ligands were 
chosen (Huang et al., 2006). The choice of appropriate decoy binding sites is critical 
for the success of this method. Choosing an obviously unfavorable site, such as a 
flat molecular surface, reduces the docking scores overall, and thus the potential to 
discriminate between ligands and decoys, while on the other hand, the choice of an 
alternative binding cavity might cause a novel mode of specific binding that does 
help to eliminate the false positives for the true binding site. The question, how to 
define a decoy binding site, such that false positive predictions for the real binding 
site are removed must remain. Further work addressing the re-ranking of predicted 
ligands may also lead to improvements.  
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7 OVERALL CONCLUSION 
 
The influenza A viruses are capable of undergoing rapid evolution due to the high 
error rate during the replication cycle, as well as the ability of undergoing genetic re-
assortments. This not only allows the virus to evade selective pressures such as the 
host immune response, but also susceptibility to antiviral drugs. Therefore this work 
has aimed to identify drug like compounds which may bind to the most evolutionary 
stable binding sites on the NS1, NEP and PB2 internal proteins.  
Taken together, the results reveal which specific regions of the NS1, NEP and PB2 
proteins display the highest levels of sequence conservation and how these regions 
are implicated in protein function and the virus life cycle overall. Furthermore, the 
analysis of predicted binding hot spots in this work has focussed on targeting sites 
other than those frequently reported in literature, such as the NS1-CPSF30 and PB2-
mGTP RNA cap snatching interaction sites (Byrn et al., 2015; Engel, 2013; Pautus et 
al., 2013; Twu et al., 2006). Starting with the NS1 protein as a potential target, two 
out of twelve predicted top hit compounds showed inhibition of H1N1 virus replication 
through plaque reduction, although their predicted target protein could not be 
confirmed. Also, new structural insights were revealed for the NEP, which showed 
that despite being a stable structure, subtle changes in side chain orientations can 
influence ligand binding hot spot locations. Overall, the predicted binding affinities 
from the docking experiments with compounds from the NCI library were higher for 
the PB2 protein (up to -10.3 kcal/mol) compared to the NEP, which suggests that the 
PB2 hot spot targeted could be a more favorable drug target site.        
Limitations in this work include the accuracy of the NS1 and NEP models and their 
conformations sampled through MD simulations, as well as the accuracy of docking 
predictions, as discussed in chapter six. Another limiting factor relating to the 
discovery of inhibitors is the compatibility of the top compounds identified with the 
antiviral assay used for validation, as shown in chapter three. The specificity towards 
the target protein is also important as the identified compounds may bind and block 
other viral proteins displaying similar structure and properties to the target site 
investigated.   
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In conclusion, this research has identified drug-like compounds predicted to bind with 
strong affinity to a region of the NS1, NEP and PB2 proteins consisting of highly 
conserved amino acid residues. Due to the low probability of the targeted regions 
undergoing genetic changes amongst different virus subtypes and hosts, such 
compounds may remain viable long-term as universal influenza inhibitors. 
Future work should be directed towards in vitro investigations to verify inhibition on 
virus replication and whether the predicted compounds could be developed into 
successful antiviral drugs. Further experiments are required to elucidate the antiviral 
mechanism of action for compounds D and K. Also, studies to test for the 
development of resistance by serial passage of the virus in cell culture with 
increasing drug compound concentrations could be performed to establish that 
influenza A viruses do not become resistant against the compounds identified. 
Potential highly conserved binding sites which are yet to be characterised could be 
investigated in research aimed at a further understanding of influenza virus biology 
and virus-host interactions. 
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9 APPENDIX 
 
9.1 NS1 amino acid conservation scores 
 
Table 18. Conservation scores for each amino acid from a multiple sequence alignment of 
NS1 protein sequences. The scores were obtained from the Jalview AAcons web server 
using Valdar’s scoring method.  
Conservation 
Score (Valdar) Residue position 
0.900 - 1.00 
(total 155) 
Met1-Val6, ser8, Phe9-Cys13, Phe14, Leu15-His17, Val18-lys20,  Leu27, 
Asp29, Ala30-Phe32, Asp34-Arg44, Gly45-gly47, Thr49-Asp53, Ile54, 
Ala57, Thr58, Gly61, Lys62, Ile64-glu66, Ile68, leu69, glu72, lys75, 
Pro80, arg83, Tyr84, Asp87-Thr89, Glu91-Trp97, Met99-Lys105, Gly108, 
leu110, Ile112-Lys121, Ile123, Leu125-Val131, Phe133, Arg135-Glu137, 
Leu139, Ile140, Leu142-Ser160, Pro162-Thr165, Glu167-Ala172, Ile173-
Asn183, Asn185,-Arg188, Thr190, Glu191, Gln194-Trp198, Glu203, 
Gly205, Pro211 
0.800-0.899 
(total 36)  
Ser7, Arg21-Asp24, Gly28, Leu33, Thr56, Gln63, Gly71, Ser73, Asp74, 
Leu77, Lys78, Ala81, Ser82, Leu85, Thr86, Leu90, Phe98, Val106, 
Cys111, Ile132, Asp134, Thr138, Leu141, Leu161, Asp184, Val189, 
Ile193, Arg199, Asp202, Arg206-Leu209 
0.700 - 0.799 
(total 18) 
Gln25, Glu26, Asn48, Glu55, Glu70, Ala76, Met79, Ser109, Thr122, 
Ile124, Thr192, Asn200, Asp204, Pro210, Asn212-Lys214 
0.600-0.699 Ala60, Arg67, Ala107, Gly166, Ser201 
<0.60 Arg59, Arg215 
 
The H5N1 A/Vietnam/1203/2004 sequence numbering convention has been used where the 
5 amino acid deletion is not included.  
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9.2 NEP amino acid conservation scores 
 
Table 19. Conservation score for each amino acid from a multiple sequence alignment of 
NEP sequences. The scores were obtained from the Jalview AAcons web server using 
Valdar’s scoring method.  
Valdar 
conservation 
score  Residue position 
 
0.90 - 1.00 
 
 
Met1, Asp2, Pro3, Asn4, Thr5, Ser8, Phe9, Gln10, Asp11, Ile12, 
Leu13, Arg15, Met16, Ser17, Lys18, Met19, Gln20, Leu21, Ser23, 
Ser24, Ser25, Asp27, Leu28, Asn29, Gly30, Met31, Ile32, Thr33, 
Phe35, Glu36, Leu38, Lys39, Tyr41, Arg42, Asp43, Ser44, Leu45, 
Gly46, Glu47, Met50, Arg51,  Gly53, Asp54, Leu55, His56, Leu58, 
Gln59, Arg61, Asn62, Trp65, Arg66, Glu67, Gln68, Leu69, Gln71, 
Lys72, Phe73, Glu74, Glu75, Ile76, Arg77, Trp78, Leu79, Ile80, 
Glu82, Arg84, Leu87, Thr90, Glu91, Asn92, Ser93, Phe94, Glu95, 
Gln96, Ile97, Thr98, Phe99, Met100, Gln101, Ala102, Leu103, His104, 
Leu105, Leu106, Leu107, Glu108, Val109, Glu110, Glu112, Ile113, 
Arg114, Phe116, Ser117, Phe118, Gln119, Leu120, Ile121 
 
0.80-0.899 
 
Val6, Ser7, Gln34, Ser37, Leu40, Val49, Met52, Lys64, Glu81, Val83, 
His85, Lys86, Lys88, Gln111, Thr115, 
 
0.70 - 0.799 
 
Glu22, Gly26, Ala48, Ser57, Gly70 
 
0.60-0.699 
 
Leu14, Asn60, Glu63, Ile89 
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9.3 PB2 amino acid conservation scores 
 
Table 20. Conservation scores for each amino acid from a multiple sequence alignment of 
PB2 protein sequences. The scores were obtained from the Jalview AAcons web server 
using Valdar’s scoring method.  
Valdar 
conservation 
score 
Residue position  
0.950-1.00 Met1-Arg8, Leu10-Pro43, Leu45-Asp60, Arg62, Ile63, Ile67, Pro68, 
Glu69, Arg70, Asn71, Glu72, Gln73, Gly74, Gln75, Leu77, Trp78, Ser79, 
Lys80,  Asp83, Ala84, Gly85, Ser86, Asp87-Arg101, Gly103, Pro104, 
Ala108-Val145, Asp146, Asn148, Pro149, Gly150, His151, Ala152, 
Asp153, Leu154, Ser155, Val172-Leu183, Ile185-Gln194, Cys196, 
Lys197, Ile198, Pro200, Leu201, Met202, Val203, Ala204, Tyr205-Val220, 
Gly222, Gly223, Thr224, Ser226-Gly247, Gly248, Val250, Asn252-
Ala270, Val272-His285, Thr287-Gly291, Arg293-Leu298, Gln300-Glu305, 
Ala307-Thr333, Gly335, Ser336, Ser337, Glu341, Glu342, Glu343, 
Leu345-Ile354, Val356-Gly367, Arg369-Leu445,  Gln447-Gly450, Glu452, 
Ile454, Asp455, Val457-Glu472, Ser474, Arg476, Gly477, Arg479-Lys482, 
Gly484-Val494,  Val496-Gln507, Gly509-Gly523, Glu525-Glu558, Lys561-
Gln566, Pro568, Thr569, Leu571, Tyr572, Asn573, Lys574, Glu576-
Ala587, Arg589, Tyr592-Arg597, Leu599-Thr612, Gln614-Pro626, 
Gln628-Gly644, Arg646, Ile647, Leu648, Arg650-Lys660, Thr662-Thr666, 
Leu668-Gly673, Leu675, Glu677-Gly682, Gly685-Glu700, Lys702-Ile710, 
Glu712-Ser714,  Leu716, Lys718-Arg755 
0.900-0.949 Asp9, Ala44, Lys61, Glu65, Met66, Thr81, Asn102, Thr106, Ala156, 
Lys157-Glu171, Ala199, Ala221, Glu249, Arg251, Ser286, Arg299, 
Gln306, Ser334, Val338, Val344, Arg355, Arg368, Phe446, Ile451, 
Leu475, Val478, Val495, Thr524, Val560, Asp567, Met570, Met575, 
Thr598, Met645, Val649, Val667, Ala674, Thr683, Asp701, Asn711, 
Asn715, Ala717, Ala757, Asn759 
0.850-0.899 Ile64, Thr76, Asn82, Ala105, Thr184, Asp195, Ser225, Lys339, Lys340, 
Pro453, Asn456, Met473, Arg508, Gln591, Val613, Lys627, Ala684, 
Met756, Ile758 
0.800-0.849 Ser107, Thr271, Ile292, Met483, Ala661, Thr676 
0.700-0.799 Ile147, Thr559, Ala588,  Gly590 
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9.4 Molecular dynamics parameter file for production run (NS1) 
 
title      = part free MD 100 ns 
 
integrator      = md    ; leap-frog Algorithm 
nsteps     = 50000000   ; 0.002*50000000 = 100 ns 
dt     = 0.002      ; 2 femtosecond time step 
nstenergy       = 1000      ; save energies every 5 ps 
nstlist         = 10    ; frequency to update the neighbor list       
rlist           = 1.0    ; short range neighbor list cut-off (in nm) 
coulombtype     = pme    ; treatment of long range electrostatics 
rcoulomb        = 1.0    ; short range electrostatic cut-off (in nm) 
rvdw            = 1.0    ; short range van der Waals cut-off (in nm)  
vdw-type        = cut-off     
 
continuation    = yes             ; continue simulation from equilibration stage 
 
nstxout     = 0     ; frequency to save output coordinates 
nstvout     = 0     ; frequency to save output velocities 
nstfout     = 0     ; frequency to save output forces 
nstlog     = 10000    ; update log file every 5 ps 
nstxtcout     = 10000    ; compressed trajectory output every 20 ps 
 
tcoupl     = v-rescale   ; modified Berendson thermostat 
tc-grps     = protein water_and_ions ; groups to couple separately 
tau-t      = 0.5 0.5    ; time constant for coupling (in ps) 
ref-t     = 300 300    ; reference temperature for coupling (K)  
pcoupl     = parrinello-rahman ; pressure coupling is on 
pcoupltype     = isotropic   ; uniform scaling of box vectors 
tau-p      = 2.0    ; time constant for coupling (in ps) 
compressibility = 4.5e-5    ; isothermal compressibility of water (bar-1) 
ref-p     = 1.0    ; reference pressure for coupling (bar) 
 
define     = -DPARTIAL   ; include partial position restraints 
refcoord_scaling = com   ; scale centre of mass of reference coordinates 
constraints    = all-bonds   ; all bonds treated as constraints  
 
gen_vel      = yes    ; assign velocities from Maxwell distribution 
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9.5 PERL script to extract compounds within a 80% similarity cut-off 
    
#!/usr/bin/perl 
 
############################################################ 
# Usage: extract.pl <file with ZINC codes> <sdf-file> 
#  
#  prints out the mol2-entry corresponding to each ZINC code 
#  contained in the file with ZINC codes 
# 
# (c) A.K. 20/01/2015, University of Hertfordshire 
############################################################ 
 
if ($#ARGV<1) { 
   print "----------------------------------------------------------------
\n"; 
   print "Usage: extract.pl <file with ZINC codes> <mol2-file>\n"; 
   print "Prints out the mol2-entry corresponding to each ZINC code\n"; 
   print "To redirect the output into a file use: > file.mol2\n"; 
   print "(c) A.K. 20/01/2015, University of Hertfordshire\n"; 
   print "----------------------------------------------------------------
\n"; 
   exit; 
} 
$ZincCodeFile = $ARGV[0]; 
$mol2File = $ARGV[1]; 
 
# read in ZINC codes 
 
%code = (); # initialises a 'hash' variable 
open (IN, $ZincCodeFile); 
while(defined($in=<IN>)) { 
     if ($in =~ m/(ZINC\w+)$/) { 
         $code{$1} = 1; 
     } 
} 
close IN; 
 
print "\@<TRIPOS>MOLECULE\n"; 
 
open (IN, $mol2File); 
while(defined($in=<IN>)) { 
  if ($in =~ m/(ZINC\w+)$/) { 
      $zinc = $1; 
      if ($code{$zinc}==1) { 
          print "$zinc\n"; 
          $line = <IN>; 
          print $line; 
          until($line =~ m/TRIPOS>MOLECULE/) {  
               last if !defined($line=<IN>);   # read next line and exit 
loop if end of file is reached 
               print "$line";   # print out lines until @<TRIPOS>MOLECULE 
is reached (incl.) 
          } 
       } 
  } 
} 
close IN; 
 
This script was written by Dr Andreas Kukol. 
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9.6 AutoDock 4 grid parameter file (NS1 protein) 
 
npts 50 70 80                             # num.grid points in xyz 
gridfld rec.maps.fld                      # grid_data_file 
spacing 0.375                            # spacing(A) 
receptor_types A C HD N OA SA             # receptor atom types 
ligand_types A NA SA C N HD OA S Br F Cl P I  # ligand atom types 
receptor rec.pdbqt                       # macromolecule 
gridcenter -5.013 -16.806 -26.516        # xyz-coordinates or auto 
smooth 0.5                               # store minimum energy w/in 
rad(A) 
map rec.A.map                            # atom-specific affinity map 
map rec.NA.map                           # atom-specific affinity map 
map rec.SA.map                            # atom-specific affinity map 
map rec.C.map                            # atom-specific affinity map 
map rec.N.map                            # atom-specific affinity map 
map rec.HD.map                            # atom-specific affinity map 
map rec.OA.map                            # atom-specific affinity map 
map rec.S.map                             # atom-specific affinity map 
map rec.Br.map                            # atom-specific affinity map 
map rec.F.map                             # atom-specific affinity map 
map rec.Cl.map                            # atom-specific affinity map 
map rec.P.map                            # atom-specific affinity map 
map rec.I.map                             # atom-specific affinity map 
elecmap rec.e.map                        # electrostatic potential map 
dsolvmap rec.d.map                        # desolvation potential map 
dielectric -0.1465                        # <0, AD4 distance-
dep.diel;>0, 
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9.7 AutoDock 4 docking parameter file (NS1 protein) 
 
AutoDock_parameter_version 4.2 # used by AutoDock to validate parameter set 
outlev 0                       # diagnostic output level 
intelec                        # calculate internal electrostatics 
seed pid time                  # seeds for random generator 
ligand_types A C HD N NA OA SA # atoms types in ligand 
fld rec.maps.fld               # grid_data_file 
map rec.A.map                  # atom-specific affinity map 
map rec.C.map                  # atom-specific affinity map 
map rec.HD.map                 # atom-specific affinity map 
map rec.N.map                  # atom-specific affinity map 
map rec.NA.map                 # atom-specific affinity map 
map rec.OA.map                 # atom-specific affinity map 
map rec.SA.map                 # atom-specific affinity map 
elecmap rec.e.map              # electrostatics map 
desolvmap rec.d.map            # desolvation map 
move ZINC04627258.pdbqt        # small molecule 
about 4.1391 -5.2778 -1.8688   # small molecule center 
tran0 random                   # initial coordinates/A or random 
axisangle0 random              # initial orientation 
dihe0 random                   # initial dihedrals (relative) or random 
tstep 2.0                      # translation step/A 
qstep 50.0                     # quaternion step/deg 
dstep 50.0                     # torsion step/deg 
torsdof 4                      # torsional degrees of freedom 
rmstol 2.0                     # cluster_tolerance/A 
extnrg 1000.0                  # external grid energy 
e0max 0.0 10000                # max initial energy; max number of retries 
ga_pop_size 150                # number of individuals in population 
ga_num_evals 350000            # maximum number of energy evaluations 
ga_num_generations 27000       # maximum number of generations 
ga_elitism 1                   # number of top individuals to survive to 
next generation 
ga_mutation_rate 0.02          # rate of gene mutation 
ga_crossover_rate 0.8          # rate of crossover 
ga_window_size 10              #  
ga_cauchy_alpha 0.0            # Alpha parameter of Cauchy distribution 
ga_cauchy_beta 1.0             # Beta parameter Cauchy distribution 
set_ga                         # set the above parameters for GA or LGA 
sw_max_its 300                 # iterations of Solis & Wets local search 
sw_max_succ 4                  # consecutive successes before changing rho 
sw_max_fail 4                  # consecutive failures before changing rho 
sw_rho 1.0                     # size of local search space to sample 
sw_lb_rho 0.01                 # lower bound on rho 
ls_search_freq 0.15            # probability of performing local search on 
individual 
set_psw1                       # set the above pseudo-Solis & Wets 
parameters 
unbound_model bound            # state of unbound ligand 
ga_run 50                      # do this many hybrid GA-LS runs 
analysis                       # perform a ranked cluster analysis 
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9.8 Python script for virtual screening with AutoDock 4 
 
import os 
import time 
from subprocess import Popen,PIPE 
 
step=100 
 
mypath=os.getcwd() 
files=open('filelist').read().splitlines() 
i=0 
while i<len(files): 
    c=0 
    # test -- write the job scripts to a file but don't run them 
    q=Popen('cat > test'+str(i),shell=True,stdin=PIPE).stdin 
    # actual run 
    # q=Popen('qsub -N AD4-'+str(i)+' -j oe -o /dev/null -l nodes=1:ppn=1 
    -l walltime=33:00:00',shell=True,stdin=PIPE).stdin 
     
    q.write('#!/bin/bash\n') 
    while c<100 and i<len(files): 
        f=files[i] 
        q.write('cd '+mypath+'/'+f+'\n') 
        q.write('/soft/autodock/autodock4 -p '+f+'.dpf -l '+f+'.dlg \n') 
        i+=1 
        c+=1 
    q.close() 
 
    time.sleep(2) 
 
 
This script was written by Prof. Martin Hardcastle (University of Hertfordshire).
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9.9 Python script for virtual screening with AutoDock Vina 
 
import os 
import time 
from subprocess import Popen,PIPE 
 
step=100 
 
mypath=os.getcwd() 
files=open('filelist').read().splitlines() 
i=0 
while i<len(files): 
    c=0 
    # test -- write the job scripts to a file but don't run them 
    q=Popen('cat > test'+str(i),shell=True,stdin=PIPE).stdin 
    # actual run 
    # q=Popen('qsub -N dock-'+str(i)+' -j oe -o /dev/null -l nodes=1:ppn=8     
-l walltime=33:00:00',shell=True,stdin=PIPE).stdin 
     
    q.write('#!/bin/bash\n') 
    q.write('cd '+mypath+'\n') 
    while c<100 and i<len(files): 
        f=files[i] 
        b='dock_'+f 
        q.write('mkdir -p '+b+'\n') 
        q.write('/soft/autodock_vina_1_1_1_linux_x86/bin/vina --config 
'+mypath+'/conf.txt --ligand '+mypath+'/'+f+' --out 
'+mypath+'/'+b+'/out.pdbqt --log '+mypath+'/'+b+'/log.txt\n') 
        i+=1 
        c+=1 
    q.close() 
 
       time.sleep(2) 
 
 
This script was written by Prof. Martin Hardcastle (University of Hertfordshire). 
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9.10 PERL script to combine virtual screening rank lists 
 
#!/usr/bin/perl 
 
 
if ($#ARGV < 2) { 
   print "-------------------------------------------------------------\n"; 
   print "Usage: JoinRankList.pl <number_of_lists> <list1> <list2> ...\n"; 
   print "Simple combination of two or more rank lists from virtual 
screening\n"; 
   print "Ligands with a higher rank (at the top of a list) preceed those 
with a lower rank.\n";  
   print "All lists should be of same length\n"; 
   print "-------------------------------------------------------------\n"; 
   exit; 
} 
$numlists = $ARGV[0]; 
for $i (1..$numlists) { 
    $list[$i] = $ARGV[$i]; 
} 
 
# read in the lists 
# AutoDock Raccoon 
# "ZINC03871916_rec/ZINC03871916_rec",-13.51 
# "ZINC03834067_rec/ZINC03834067_rec",-13.31 
# .... 
# Vina 
# dock_ZINC01539579.pdbqt -13.3 
# dock_ZINC01540632.pdbqt -13.1 
# 
 
# read in ranked lists 
 
for $i (1..$numlists) { 
    $rank = 0; 
    open (IN, $list[$i]); 
    while(defined($in=<IN>)) { 
         $rank++; 
         $in =~ m/^.*(ZINC[0-9]+)[-\._:\n +]/; 
         $LigandRank[$i]{$1} = $rank; 
         $LigandName[$i][$rank] = $1; # note that ligands names are in rank 
order 
    } 
    close IN; 
} 
$lengthOfList = $rank; 
 
# print new list 
 
%NewList = (); 
for $i (1..$lengthOfList) { 
        for $j (1..$numlists) { 
            $name = $LigandName[$j][$i]; 
            if (not exists ($NewList{$name})) { 
               print "$name\n"; 
               $NewList{$name} = $LigandRank[$j]{$name}; 
            } 
        } 
} 
This script was written by Dr. Andreas Kukol 
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